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Solid organ transplant has emerged over the last half century as an important
treatment for solid organ failure. Management has matured dramatically over the past two
decades with improvements in acute rejection, but long-term graft survival has improved very
little and current treatment is limited by the side-effects and toxicities of immunosuppressive
medications. Nanoparticle delivery of therapeutics, improving transport characteristics and
decreasing systemic and local toxicity has emerged as a dynamic treatment modality, but
little work has been done using nanoparticles in transplantation. Our research examined the
use of CD4-targeted nanoparticles encapsulated with mycophenolic acid (MPA), a commonly
used immunosuppressant in organ transplantation. This work is the first to examine antigenspecific targeting of nanoparticles in any transplant model. MPA-loaded particles show a
slow and continuous release profile and biodistribution suggested retention in the spleen.
Targeting of nanoparticles to CD4 T cells was suggested using ex vivo and in vitro flow
cytometry. In the fully allogeneic MHCII mismatch BALB/C to C57BL/6 mice we found
improved graft survival in the non-targeted MPA group and even greater graft survival in the
CD4-targeted group. Targeted and non-targeted particle groups showed equal delay in
rejection in the less immunogenic single MHC mismatch B6.H-2bm12 to C57BL/6 model that
we showed to be CD4 dependent. In both models, graft survival times were increased over
free drug and controls with roughly one thousand fold lower dose of drug in the nanoparticles
as compared with free MPA. Consistent with these findings were decreased proliferation
with targeted and non-targeted MPA-nanoparticles using in vitro and ex vivo mixed
lymphocyte reactions. We postulated that the similar rejection times in targeted and nontargeted groups was due to dendritic cell (DC) involvement and we found active uptake of
nanoparticles in DCs, a decrease in inflammatory cytokine production and a decrease in
treated DCs ability to stimulate T cells via mixed lymphocyte reactions. Furthermore we
found a possible mechanism in the DC interaction with T cells through the upregulation of the
inhibiting co-stimulatory molecules B7-DC and B7-H1 on DCs treated with MPAnanoparticles. We also found possible upregulation of CD4+CD25+ Foxp3 expressing Tregs
which may serve to increase graft acceptance. These results explore the involvement of
dendritic cells in the process of nanoparticle-induced graft acceptance and suggest the
feasibility of using nanoparticle drug vectors in clinical transplant.
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Introduction
Solid organ transplantation in humans has emerged over the past few decades
as a major advance in life-saving treatments for a number of diseases (1), (2). Lung
transplants treat incurable cystic fibrosis (3) and other pulmonary disorders, heart
transplants, liver and kidney transplants treat a number of diseases that would
eventually lead to patients death (4). Great advances have been made in the basic
science understanding that we currently have of major and minor histocompatability, and
the mechanisms of graft rejection. These advances have helped to improve both graft
survival and long-term recipient survival (4). Medical treatment of transplant rejection
has been primarily through immunosuppressive drug modalities to delay acute rejection.
While usually successful at initially maintaining graft survival, long-term survival is often
limited by patients' intolerance to the side-effects of chronic immunosuppression (5).
Increased susceptibility to opportunistic infections limits chronic treatments. Additionally,
immunosuppression leads to increased incidence of solid and hematologic neoplasms
(6).

Direct toxicity of these medications can lead to severe hypertension, diabetes,

nephrotoxicity and many other severe complications and worsen the risk benefit ratio of
long-term treatments.

Therefore improvements in immune suppression after organ

transplantation are clearly required.
With this in mind, the goal of treatment would be to reduce systemic toxicities and
side-effects while maintaining therapeutic doses to the organ or cell population of
interest.

Traditional treatment modalities use systemic delivery and generally have

narrow a therapeutic index. With variable bio-absorption and bio-availability, traditional
systemic delivery of drug often falls outside of this narrow index with difficulty balancing
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efficacy and toxicity. Moreover, the efficacy of systemic drug delivery is hampered by
genetic polymorphisms (7), up-regulation of drug efflux pumps and development of
resistance (8).

With these problems as the driving force, nanoparticles have been

utilized as a method of encapsulating toxic drug, allowing specific delivery and
decreasing side-effects.
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Background
Transplantation
In the 2000's there have been between 13,000 to 17,000 kidney transplants per
year in the US (9). Liver transplants are the second most common with 5,000 to 7,000
per year.

Heart transplants are third most common (1800-2300) and lung is fourth

(1000-1500). Other solid organs such as pancreas and intestine, as well as combined
transplants (heart/lung or kidney/pancreas) are less common (9). In 2008, only 6,000 of
the 22,000 transplants were done with living donors, with the remaining from deceased
donors, despite the dramatic difference in graft survival between living and deceased
grafts (9).
The first successful solid organ transplantation was a kidney allograft in 1954 (4).
By the end of the 1960's, liver, lung, heart and pancreas transplantation was operatively
successful as well, despite extremely poor post-operative graft and host survival. In the
mid 1970's cyclosporine was discovered by Jean Borel (10) and after approval in 1983
became a major breakthrough in the medical management of transplantation (11). Prior
to this breakthrough, post-op survival times were dismal for patients receiving solid
organ allografts. In the last twenty years our understanding of the immune system has
allowed for human leukocyte antigen (HLA) typing and research has uncovered organ
specific responses to transplant that have improved management.

Organ specific

metrics and measures by which to follow transplant function and rejection have been
developed as well, and further drug development has created more immunosuppressive
medications (4).

These advances have continued to improve post-transplantation

survival of patients. One study looked at changes in renal graft survival from 1988 to
1998. They found an improvement from 89.7% to 94.3% one-year-survival in living
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donors, and an improvement from 76.0% to 89.3% one-year-survival in cadaveric grafts.
These improvements occurred despite the use of older donors (which generally worsens
graft function) in this study. There was also an overall decrease in acute rejection
episodes which can be an important predictor for late rejection (12). Outcomes in other
solid organ transplants such as heart and liver have similarly improved as medical
management has evolved (4).

Transplant Rejection
There are generally three types of transplant rejection that are commonly seen:
hyper-acute reactions immediately following reperfusion, acute rejection occurring days
to years after surgery and chronic rejection that takes many years to manifest. Hyperacute rejection occurs within minutes of the transplantation and is mediated by
preformed antibodies against the tissue leading to rapid rejection. ABO blood type
incompatibility is the most common cause of hyper-acute rejection, but it can also occur
due to alloantibodies against major histocompatability complex (MHC) (Human leukocyte
antigen or HLA is the human form of MHC). Preformed antibodies bind to the graft and
the complement cascade is triggered, leading to complement-mediated destruction of
the graft tissue (13).

The blood clotting cascade is also initiated which leads to

thrombosis and interruption of blood flow in the vascularized graft and tissue ischemia.
In cases of hyper-acute rejection the graft must immediately be removed in order to
prevent a systemic inflammatory response.

This type of rejection is generally

preventable by careful HLA and ABO matching and measurements of allograft-specific
antibodies, but is not acutely treatable (13)

Kassis, Elias

Page 10

Acute rejection occurs from weeks to years after the transplant surgery. It is
generally thought to be caused by HLA mismatch between graft and host. Even in
carefully matched transplants, it is difficult to fully match all HLA types, and minor histoincompatibility is likely present even in the best HLA matches.

Acute rejection is

common in all transplantation and does not usually lead to loss of the graft (14). A single
episode if treated promptly is not a cause of concern; however, recurrent episodes have
been shown to lead to increases in chronic rejection.
Acute rejection unlike hyper-acute rejection is a T cell dependent process. T
cells can be activated through a direct and an indirect pathway. The indirect pathway
occurs when host antigen presenting cells (APCs) such as dendritic cells, phagocytose
foreign particles such as graft tissue. The host APCs migrate to the lymph nodes and
spleen and present the foreign proteins via MHCII to T cells (Figure 1). The direct
pathway occurs when resident donor APCs within the graft directly display foreign self
protein via MHC to host T cells (Figure 1). In either pathway, the antigen specific T cell
population is activated and T cell populations are increased that will target the graft
tissue. CD8 cytotoxic T cells activated by MHCI and CD4 T cells activated by MHCII
upregulate the inflammatory response through macrophage activation as well the
humoral response. The direct pathway is thought to be more involved in acute rejection
with direct T cell toxicity likely due to the higher frequency of directly allospecific T cells,
but the indirect pathway is also involved in acute rejection. Indirect activation causes T
cell activation, macrophage-induced tissue injury, fibrosis and alloantibody formation
(15), (16) (13).
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Figure 1. Schematic depicting
methods of allorecognition in
transplant rejection. Direct
Presentation: Post
transplantation, dendritic cells
(DCs) from the donor leave the
graft and circulate via
lymphatics to regional lymph
nodes and via blood vessels to
the spleen. DCs present
peptides from the donor on
their own major
histocompatibility complex
(MHC) to the T-cells of the
recipient, binding to the host Tcell receptor (TCR). Direct
presentation brings about an
alloreactive T-cell population
that recognizes and kills the
graft. Indirect Presentation:
Post transplantation, host DCs
migrate into the graft, and take
up and process proteins from
recipient cells. These host
DC's migrate back to lymph
nodes and spleen and present
foreign peptides on self MHC,
leading to an allo-specific
response (15).

Chronic rejection occurs over very long periods of time leading to progressive
vascular damage and insufficiency, concentric arteriosclerosis of graft vessels and
parenchymal fibrosis and atrophy.

Chronic rejection may be due to antigen-specific

alloreactivity and antibody deposition, but may also be due to non-specific late effects of
ischemia-reperfusion injury, long-term side-effects of cytotoxic drugs such as
cyclosporine and even infection with cytomegalovirus. It has also been shown that the
indirect pathway of allorecognition is involved with the pathogenesis of chronic rejection
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as well (17). Unfortunately, chronic rejection is generally not amenable to treatment, and
is the major cause of late graft dysfunction, occurring many years post-transplant.

It is

due to chronic rejection that despite improvements in short-term graft survival, long-term
survival has seen little improvement, with a renal transplant half-life survival remaining at
roughly 8 years (18), (5).

Medical Treatment of Rejection
Current medical management of transplant is aimed at modulation of acute
rejection. Acute rejection is usually treated with short bursts of high-dose steroids which
is often sufficient to prevent the rejection from progressing. Maintenance therapy is
given to most patients which consists of chronic immunosuppression using multiple
drugs in combination; often as “triple therapy”. Triple therapy includes a steroid with the
addition of a calcineurin inhibitor such as cyclosporine or tacrolimus and an
antiproliferative agent such as mycophenolate mofetil. Maintenance therapy serves to
not only treat acute flares of rejection, but to prevent them from initially occurring. In
some patients in which calcineurin inhibitors and steroids are contra-indicated, mTOR
(mammalian target of rapamycin) inhibitors such as sirolimus may be substituted. In
high risk patients, antibody treatments may be added as well to augment the response.
The section below will briefly describe the types of medications currently available.
Corticosteroids: These medications are derivatives of the glucocorticoid family of
steroids. The most commonly used is prednisone which is a synthetic analog of cortisol,
and all drugs in this class share similarities in structure and function. They act via
intracellular receptors that regulate transcription of specific genes. Up to 1% of genes
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can be regulated by glucocorticoids, which cause a complex set of physiological effects.
Their role in immune modulation lies in their ability to do the following: decrease IL-1, IL3, IL-4, IL-5, IL-8, TNF-alpha and GM-CSF causing reduced inflammatory response, and
reduced activation of the immune system.

Decreased phospholipase A2 and

cyclooxygenase also serve to decrease prostaglandins and leukotrienes (13). Steroids
decrease adhesion molecules causing reduced emigration of WBC's out of blood
vessels and increase the production of endonucleases causing increased apoptosis in
lymphocytes. The negative side effects however are numerous, especially with longterm use.

These include weight gain, diabetes, hypertension, fluid gain, electrolyte

abnormalities, bone loss and skin thinning (19).

The benefits therefore need to be

carefully balanced against the side effects with long-term use.
Calcineurin Inhibitors: These medications block the calcium activated enzyme
calcineurin, which is essential for the production of IL-2. T cell growth is mediated in
large part by activation with IL-2,
proliferation.

so calcineurin inhibitors serve to decrease T cell

They work very effectively to decrease the T cell response in acute

rejection. These inhibitors also decrease IL-3, IL-4, GM-CSF and TNF-alpha, and inhibit
B-cell proliferation (13). Cyclosporine and tacrolimus are the two drugs in this class that
are commonly used in clinical transplant.

Despite their more specific effects as

compared to steroids, they can be very toxic as well especially to the kidneys and other
organs. Tacrolimus is considered more powerful than cyclosporine and has a slightly
better side-effect profile and is now used more frequently (20).
mTOR inhibitors: Instead of blocking the release of IL-2 as calcineurin inhibitors
do, these medications bind to the mTOR complex thereby inhibiting the response to IL-2
and blocking proliferation of T and B cells. Sirolimus (also known as rapamycin) is the
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major drug in this class.

It is considered less toxic than the calcineurin inhibitors

especially to the kidneys, and is generally well tolerated despite profibrotic and
prodiabetogenic effects(20).
Antibody Treatments: These drugs are the latest in targeted therapies, and can
specifically interfere with immune responses with less toxicity. Older versions like antilymphocyte globulin have been used for years as a non-specific treatment that can
remove unwanted lymphocytes (they lack specificity however, and remove nonallospecific lymphocytes as well), but their use has been limited by side effects like
serum sickness which is due to antigenicity after production in horses. However, more
specific antibody treatments have developed as well. OKT3 is no longer commonly used
due to a serious cytokine release syndrome and long term lymphoproliferative disorders,
but was effective at specifically binding to T cells in the modulation of acute rejection.
More recently, drugs like daclizumab have been created, employing a similar strategy to
mTOR and calcineurin inhibitors by blocking IL-2, but instead via direct binding to its
alpha subunit.

The main advantage of these appears to be their reduction in

opportunistic infection risk. (20) (13)
Antiproliferatives:

These drugs are widely used in transplant and include

mycophenolic acid, azathioprine and cyclophosphamide. They inhibit DNA synthesis
and exert the majority of their pharmacologic action on rapidly dividing tissues.
Azathioprine is converted within the body into a purine antagonist that competes with
inosine monophosphatase inhibiting the synthesis of purines and decreasing DNA
synthesis (13). Cyclophosphamide is an alkylating agent that directly incorporates itself
into DNA . Both have numerous toxicities and side effects, with cyclophosphamide sideeffects including hemorrhagic cystitis and bladder cancer (13).
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Mycophenolic acid (MPA) has helped to dramatically decrease the incidence of
acute rejection when used in combination with other medications. It has been approved
for use in the prevention of acute rejection in renal, liver and heart allografts, and will
likely soon be approved for use in pancreas and lung transplants as well (21). It is now
being considered an excellent alternative to the older azathioprine, with better treatment
of acute rejection.

MPA blocks inosine-5'-monophosphate dehydrogenase (IMPDH),

inhibiting the creation of guanosine. Lymphocytes lack the salvage pathway for creation
of purines and are therefore stalled in their replication, with subsequent decreases in T
cell proliferation and decreases in Ig production by B-cells (21). Furthermore, MPA has
been shown to cause apoptosis in T cells (22), and affect other aspects of the immune
system and inflammation as well. MPA has been shown to decrease the dendritic cell
response, decrease maturation and prevent antigen presentation.

It also has been

shown to reduce monocyte proliferation and recruitment into sites of inflammation (21),
and to decrease general inflammation through its actions on macrophages, decreasing
nitric oxide and superoxide formation. MPA has also been shown to decrease arterial
smooth muscle proliferation which can contribute to graft arteriopathy and rejection (22).
It is used clinically in its pro-drug formulation as mycophenolate mofetil (MMF) which
which is converted into MPA in the liver and was designed for use because of its
superior bio-absorption.

MPA has minimal side-effects compared with many other

immunosuppressives which has made it an attractive medication.

The side-effects

however include infection risk, GI toxicities, thrombosis and rare severe complications
(20).
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Overview of Nanosystems
Nanotechnology was first discussed in 1974 by Norio Taniguchi in his paper “On
the Basic Concept of Nano-technology”. He defined the technology based upon small
particles in the nanometer range in size that behave as an individual unit in terms of their
chemical and physical properties (23). As material technology has advanced, these
particles have been created from numerous substances including metals, plastics,
organic molecules, inorganic molecules like silica and a multitude of other substances.
Due to this variability in design, the individual properties and functions of nanoparticles
can be enormously different.

Nanomedicine gained interest as an off-shoot of this

technology for use in both diagnostic imaging as well as drug delivery, and over the past
two decades there has been an explosion in research and development (24), (25), (26).
In particular, there has been considerable focus on using nanoparticles for drug
delivery.

Nanoparticles serve as an optimal drug delivery vector for a number of

reasons. The creator has structural control over the size and shape of the drug cargospace and the particles can serve as a precise scaffold or container with high drug
carrying capacity; important in having plasticity in drug delivery. They can be made to be
biocompatible with nontoxic polymers, allowing for non-immunogenic, non-toxic delivery
within the body. They can have well-defined modifiable functionality for targeting with
antibodies and ligands specific to any tissue or cell type within the body leading to
decreased doses to tissues that may be sensitive to the drug, and increased doses to
the tissues of interest. The nanoparticles can be created to undergo cellular adhesion,
with subsequent endocytosis, and trafficking to allow delivery of drugs into the cytoplasm
or nucleus.

They can have well controlled and reproducible bioelimination or

biodegradation, which is extremely important in understanding how to reproducibly
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deliver drug for treatment. The nanoparticles can be developed to have controlled or
triggerable drug release.

Nanoparticles isolate and protect the encapsulated drug

against inactivation during transit through the body to target cells. They can be designed
with minimal nonspecific cellular and blood-protein binding properties in order to
decrease non-specific uptake, decrease systemic doses and increase local doses. The
nanoparticles can be created for easy and consistent reproducibility and synthesis.
They can improve solubilization of the drug that may be non-soluble. They can be
created for introduction via noninvasive routes.

Ultimately these particles can have

improved bioavailability and release profiles with reduction in administered drug doses,
improving safety and diminishing side effects. Lastly, nanoparticles are an optimal drug
delivery mechanism because they can be used as sustained release vectors, possibly
improving compliance, quality of life and outcomes. Successful nanosystems also have
the potential to evolve as we discover new proteins, receptors and ligands involved in
diseases, offering opportunities to achieve drug targeting with newly discovered diseasespecific targets (7).

Liposomal Particles
Liposomal particles are currently in use commercially for drug delivery of
chemotherapeutics and antibiotics, and have long been studied for improving drug
toxicities and delivery characteristics. These nanoparticles are composed of amphiphilic
phospholipids that form bilayers with encapsulation of an aqueous interior. These small
(80 to 100 nm) particles can be loaded with hydrophobic substances within the bilayer or
hydrophilic substances within the aqueous core. Loading of drugs is achieved through a
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that allow for encapsulation of drugs such as vincristine,

doxirubicin and amphotericin (27) (28). The first generation of liposomal particles had
the trouble of being rapidly cleared by the body due to rapid opsonization and uptake by
the mononuclear phagocytic system. This issue was addressed with the use of polyethylene glycol (PEG) (8) coating which “hides” the particles from immune uptake and
enhances distribution and bioavailablitity (29).

PEGylated particles were found to

localize in tissues with newly formed vasculature and in this localization a “passive
targeting” (30) was found which underlies the utility in liposomal anti-cancer therapies
causing relative increases in drug concentration within the leaky vasculature of tumors
as compared with the normal vasculature of healthy tissues (31) (24). Furthermore,
liposomal particles have the potential to be targeted via addition of antibodies onto their
surfaces.

There is much ongoing research looking at the utility of targeting drug

encapsulated liposomal nanoparticles.

However, liposomal systems in general have

some disadvantages in terms of drug delivery. There is generally poor control over
release of the encapsulated drug into the blood, causing unintended leak. There are
also questions about the efficiency of encapsulation and the stability of the particles
during longer storage(32)(33).

Dendrimer Particles
Dendrimer particles are polymerized branching structures emanating from a
central core that roughly form a sphere in shape (34).

The branching creates a

labyrinthine core that can be utilized for entrapment of small substances. Furthermore,
the terminal ends of the branches can be utilized and made functional via binding with
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Figure 2. A schematic created by our collaborators in the laboratory of Dr Fahmy. These represent the
three more commonly used types of nanoparticles in medical practice. A. Liposomal systems are
widely used in medicine with encapsulation of drugs such as doxirubicin and amphotericin. These
particles consist of a lipid bilayer and an aqueous core. Hydrophobic drug can be carried within the
phospholipd bilayer and hydrophilic drug can be carried in the core. B. These are solid
biodegradeable polymer based nanoparticles such as those made with poly-lactic and glycolic acid
(PLGA). These are flexible systems that allow for surface bound antibody targeting, central drug
carrying and a controlled half-life. C. Dendrimer particles are finely branched structures with a central
core. The branching creates a labrynth core for drug delivery and the ends of the branches can be
functionalized with antibody for specific targeting.

ligand, antibodies, and imaging enhancing molecules. Our collaborators, Dr Fahmy and
his lab have used these particles extensively, where they have utilized a
polyamidoamine (PAMAM) dendrimer with PEG attached to the core for targeting T cell
populations by coupling streptavidin to the terminal chain and using biotinylated
antibodies against CD3 and peptide/MHC complexes. With doxirubicin bound to the
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particles, their lab found excellent inhibition of polyclonal and antigen-specific T cells
(32).

Solid Biodegradable Particles
Polymerized

particles

appear

to

have

many

advantages

including

biocompatability, biodegradability and functionalization with loading and targeting (35).
Encapsulation using polymerized nanoparticles gives the operator specific and
reproducible control of the biodegradability and release of the internalized drug (35).
There are currently numerous materials used in the formulation of these types of
nanoparticles, but particles made from polymers of lactic and glycolic acid (PLGA) will be
focused on in more detail. These particles combine a hydrophobic poly-lactic acid (PLA)
polymer with a hydrophilic poly-glycolic acid (PGA) polymer. These are desirable to
utilize in a drug delivery system due to the fine control of the drug delivery that can be
obtained by changing the relative ratios of each substance within the nanoparticle. PLA
has a half-life of months and PGA of days, thereby giving the operator a range of options
in terms of drug release by changing the PLA:PGA ratio (36).

Drugs can be

encapsulated and attached in a variety of ways including hydrophobic entrapment and
direct conjugation to the PLGA surface, allowing a wide variety of substance to be
brought together in one functionalized nanoparticle unit (37). Furthermore, this material
has been shown to be safe in humans in thirty years of use (38) (39). The breakdown
products of these particles, lactic and glycolic acid are physiologically normal substances
involved in the Krebb cycle and are broken down into carbon dioxide and water without
affecting normal cellular functions (40).
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Micro-sized PLGA particles encapsulated with chemotherapeutic drugs have
been shown to have improved drug efficacy compared with free drug (41).

PLGA

nanoparticles loaded with doxirubicin was shown to have prolonged release profile over
a month and a similar effectiveness with in vivo injections in mice (42). Not only have
PLGA particles been shown to improve drug delivery, but they have even been found in
one paper to increase drug efficacy in cancer cell lines reversing multi-drug resistance
(43). Currently, PLGA particles are found in clinical use as a depot form of GnRH called
Lupron® (44).
Our collaborators in Dr Fahmy's lab have developed the ability to create nanosized PLGA particles (Figure 3, 4), with encapsulation of both doxirubicin and
mycophenolic acid, and direct conjugation of streptavidin onto the PLGA surface. With
the addition of streptavidin, they have created a system that can attach any biotinylated
antibody to the surface of the particle, theoretically allowing for targeting any moiety of
interest that has a commercially manufactured biotinylated antibody (45) (32). They
have also added PEG to the surface to improve circulation of the particles. Previously
these particles were too difficult to manufacture and attach PEG. PEGylation has been
shown to be very important in nanoparticle drug delivery by increasing transit times and
decreasing non-specific uptake and binding throughout the body. The development of
PEGylated solid biodegradable nanoparticles has lagged behind the development of
liposomal PEGylated particles due to the technical difficulties in attachment to the
surface and creation of functionalized particles (35). Our collaborators have successfully
developed a technique that reliably and reproducibly functionalizes PLGA particle
surfaces (Figure 3). They recently published a paper using PLGA encapsulation of
doxirubicin where they were able to improve on the cytotoxicity while decreasing the
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non-specific cardiotoxicity (35).
Dr Fahmy's lab has also been looking at targeting T cells for both imaging and
drug delivery using these particles and antibodies against CD3 (46).

Their lab

suggested that due to their small size, the PLGA particles would be internalized into the
T cells and would act as an intracellular drug reservoir allowing for sustained local
release affecting only the cell population of interest. In their work they found the CD3
targeted particles encapsulated with doxirubicin were able to decrease proliferation of T
cells after CD3 stimulation showing successful targeting and delivery of drug (32).
These particles are also gaining attention by our collaborators as potential vehicles for
vaccine delivery. The nanoparticles containing the viral proteins are internalized by both
dendritic cells (DCs) and T cells which then become activated to prime a potent adaptive
immune response (47)(48).

Figure 3. Electron Microscopy
of [lactide-co-glycolide] (PLGA)
particles. Particles w ere
created in the lab of our
collaborator Dr Fahmy.
Production of PLGA
nanoparticles results in small
particles w ith an average size
of 130nm. These particles can
be encapsulated w ith a variety
of substances including
fluorescent imaging molecules
such as rodamine and
coumarin-6, drugs such as
mycophelonic acid (MPA) and
doxirubicin, and magnetic
resonance enhancers such as
gadalinium. The surface of the
particles is used for
attachment of avidin, and this
can be utilized for the
attachment of biotinylated
antibodies.
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Nanomedicine in Transplantation
The majority of research into nanoparticle drug delivery has examined uses in
cancer treatment and diagnosis. The literature on nanoparticles in transplant rejection is
far more limited. Very few studies were found in an extensive literature search on the
use of nanoparticles in modulation of transplantation. One group has looked at PLA
nanoparticles stabilized with cholesterol-modified chitosan encapsulated with rapamycin
in a corneal transplantation rabbit model.

This group found that the nanoparticles

exhibited excellent retention in the precorneal area allowing for sustained release of
rapamycin. When compared to topical free rapamycin they found significant efficacy in
the treatment with similar (but slightly improved) mean survival times of the grafts (49).
Two other groups looked at cyclosporine formulated into PLGA particles for use in
corneal transplants. Both sets of researchers found significant increases in mean graft
survival times in animals receiving the nanoparticles loaded with cyclosporine(50)(51)
(52).

Using PLGA encapsulated with tacrolimus, another group has also looked at

corneal transplant rejection. Similarly to the groups using other immunosuppressives,
PLGA loaded with tacrolimus delayed graft rejection and improved mean survival times
(53).
Using liposomal encapsulations of tacrolimus and rapamycin, one group of
researchers have published a number of manuscripts looking at modulation of transplant
rejection in dopaminergic grafts in a Parkinson disease mouse model. These papers
found decreased immunorejection of grafts in groups receiving treatment with
liposomally encapsulated drug (54)(55)(56). Another group has been using liposomal
preparations of tacrolimus in an islet cell transplantation model. They found significantly
delayed graft rejection after using the liposomal formulation (57). This same Canadian
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group also published a brief report indicating the improved side-effect profile and
delayed skin and heart transplant rejection using oral liposomal tacrolimus (58). There
have not been any skin or solid organ transplant models that utilize PLGA particles.
There is also a small body of research relevant for transplant that does not
directly use a transplant model.

One study of interest looked at nanoparticles and

immune modulation, examining the role of PLGA particles loaded with rapamycin and
their activity against dendritic cells. Interestingly as compared with free rapamycin which
has little affect on dendritic cells, PLGA loaded drug caused a decrease in maturation
markers such as MHC II, CD86 and CD40. In addition, PLGA delivered rapamycin
decreased cytokine production and decreased T cell proliferation using mixed
lymphocyte reactions (59).

This same group has also used PLGA encapsulated

rapamycin particles and looked at the expression of ICAM-1, an important adhesion
molecule that facilitates the interaction of T cells with dendritic cells. They found that
PLGA particles but not free-drug were able to down-regulate the expression of ICAM-1.
Furthermore they found an immunosuppressive array of cytokine production with the
rapamycin loaded PLGA particles (60).
Most other work in nanoparticles that is relevant to transplantation involve studies
examining the encapsulation of immunosuppressive medications, but these studies do
not directly look at their application in post-transplant treatment. One group successfully
used PLGA encapsulated rapamycin (sirolimus) in a vascular re-stenosis model and
were able to increase anti-proliferation with PLGA loaded drug as compared to free drug
(61).

Another group has looked at the use of oral PLGA particles loaded with

cyclosporine. This study looked at pharmacokinetics and also found decreased renal
toxicity in the oral nanoparticle drug vector as compared with the standard drug delivery
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(40).

Research Question and Design
Our study examined the use of PLGA nanoparticles encapsulated with
mycophenolic acid for the modulation of transplant rejection in a murine skin transplant
model. We chose to use PLGA particles as these are considered by many (including our
collaborators) to be the best system for sustained release, specific targeting, future
clinical utility and can now be manufactured by our collaborators using what they
consider a superior technique with the addition of PEGylation (35). We chose to use
mycophenolic acid as our immune modulator as it is commonly used clinically and our
collaborators have had success with its encapsulation within the PLGA particles. They
have previously been working on using PLGA encapsulated with MPA in a lupus mouse
model with preliminary results that have looked excellent (unpublished data). We chose
to do skin transplants in mice as this is a commonly used model for transplantation that
has relative technical ease. The skin transplants are highly immunogenic and their
resistance to modulation makes them an excellent candidate for testing immune
modulating treatments (16, 62). Furthermore, our lab has had great experience using
this model in the past (63). As such, we looked at the use of MPA loaded particles, both
targeted to CD4+ T cells and non-targeted, and compared the use of these particles to
empty particles, free doses of MPA and non-treatment groups.

We examined skin

transplants in a major MHC mismatch BALB/C to C57BL/6 model as an initial test of
MPA loaded particles to effect a response. We also wanted to test the ability to target
specific cell populations using the targeted MPA particles. To accomplish this we used a
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CD4-dependent transplant rejection model, using a less immunogenic single MHCII
mismatch model with B6.H-2bm12 (spontaneous mutation of I-Ab region causing prompt
rejection) to C57BL/6 mice. Our hypothesis was that specific targeted drug delivery via
nanoparticles would increase graft acceptance and increase the mean survival times of
transplanted skin in both our high and low immunogenic models. Our secondary aims
were to analyze the role of cytokine signaling between treatment groups, analyze the
expression of surface markers using flow cytometry and assess T cell proliferation with
different treatment groups using mixed lymphocyte reactions. When our results showed
that non-targeted nanoparticles also improved graft acceptance, we examined the
impact of nanoparticle therapy on dendritic cells, particularly how particles impact
costimulatory and coinhibitory pathways that DCs use to modulate T cell responses in
rejection.
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Experimental Methods
Animals
All animals used were housed in the Anlyan Center Animal Facility, and used
according to Yale University IACUC protocol.

BALB/C (H-2d), C57BL/6 (H-2b) and

B6.H-2bm12 (H-2bm12) mice were purchased from the National Cancer Institute for our
experiments and CD4 knockout mice from Jackson Labs. B6.H-2bm12 mice are a strain
with a spontaneous mutation of the I-Ab molecule resulting in a 3-aa substitution in the
hypervariable region of the Aβ chain. They are otherwise identical to C57BL/6 mice. All
animals were housed under pathogen-free conditions, and animals were not used if they
had any skin lesions or other signs of sickness.

Nanoparticles
All nanoparticles were created in the lab of Tarek Fahmy, by our collaborator
Michael Look, a PhD candidate in Bioengineering.

Nanoparticles were made of

polymers of lactic and glycolic acid, with avidin impregnated into the surface. 20 mg of
dry MPA was added in 400 uL of methanol (50 mg/mL stock) and subsequently added to
2 ml ethyl acetate containing 200 mg polymer and the methanol was evaporated off.
Dropwise, 2mL of organic phase of MPA/PLGA/ethyl acetate was added to 4 mL of a
3.75% PVA solution containing 5 mg palmitate-avidin under vortex. The solution was
sonicated under ice at 38% amplitude, 3X for 10 seconds to form an emulsion.
Nanoparticles were added to a beaker of 100 mL of 0.3% PVA and stirred in the dark for
3 hours at room temperature. After 3 hours of incubation, particles were collected into
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centrifuge tubes and spun at 12000 rpm for 12 minutes at 4ºC.

Supernatant was

dumped and particles thoroughly resuspended in ~40-50 mL d.i. water using a sonicator.
Particles were spun and washed once. Particles were collected in a single 50 mL falcon
tube in ~5-10 mL d.i. water. Particles were passed through a 40 um filter to remove
aggregates (and PVA debris), and frozen at -80°C for at least 1 hour. Particles were
lyophilized for 48 hours in the dark. The nanoparticle yield from this protocol had a
theoretical maximum avidin coverage of 25 ug avidin-palmitate per mg of polymer.
Coumarin-6, and rhodamine particles were created similarly but with loading of dye
instead of drug (Figure 4) for fluorescent imaging.
In preparation for injection into mice for treatment of transplant rejection,
nanoparticles were prepared for targeting or non-targeted groups.

All nanoparticle

preparation prior to injection was done by either Dr. Anushree Shirali, (nephrology
fellow), or Elias Kassis. In the targeted groups biotinylated RM4-4, a monoclonal nondepleting antibody binding CD4 was attached to the streptavidin moieties of the
nanoparticles.

Nanoparticles were weighed, suspended in PBS and incubated with

RM4-4 antibody at a concentration of 7.5ul (0.5mg/ml) biotin per 1mg particle.

PEG

was added at 1:1 molar ration(M.W. 10000) at 0.75 ul (5mg/ml). After 30 minutes at
room temperature, particles were spun down, the supernatant removed and the particles
re-suspended in PBS to obtain an injection dose of 20mg/ml (250 ml injection:
5mg/animal). The non-targeted particles were incubated with PEG alone. MPA-loaded,
empty, coumarin-6 and rhodamine particles were prepared identically for drug delivery
and fluorescent imaging.
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MPA

MPA

Figure 4. Figure
taken from our
collaborators (35),
showing a schematic
of PLGA nanoparticle
creation. A) Synthesis
of avidin-lipid
conjugate. Avidin is
reacted with palmitic
acid–NHS in a 2%
deoxycholate buffer to
form avidin-palmitate
conjugate. (B) The
conjugate is then
added during the
aqueous phase of a
modified singleemulsion technique to
form avidin-coated
PLGA nanoparticles
(C) Avidin-coated
nanoparticles can then
be incubated in
solution with
biotinylated ligands to
form surface-modified
nanoparticles.

MPA Release From Particles
This experiment was done by Michael Look in the lab of Dr Tarek Fahmy. 1-10
mg/ml of MPA-loaded particles were prepared in PBS. The particles were place in a
microcentrifuge tube and placed on a shaker at 37ºC. Once per day the tubes were
spun at 13200 rcf for 10 minutes. The supernatant was collected and stored at -20ºC
until ready for use. The pellet was resuspended in 1ml PBS and allowed to incubate for
24 hours until the next supernatant collection.

This continued for one week.

The

supernatants were analyzed for MPA on a SpectraMax M5 plate reader (Molecular
Devices) with excitation 340nm and emission 450nm with these data points plotted to
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determine MPA release.

Transplantation
All transplantation was performed by either Elias Kassis (BALB/C) or Dr
Anushree Shirali (B6.H-2bm12 mice). On the day of transplantation, donor mice were
shaved, cleaned with alcohol and iodine and sacrificed using isofluorane, and skin was
removed. Fascia was cleared from under the dermis and skin was placed in PBS on ice
until ready for transplant. Recipient mice were anesthetized with isofluorane shaved,
cleaned with alcohol and betadine. With fine scalpels a 2x2 cm square area of skin was
removed from the right dorsal thorax. The donor skin was cut to size and attached to the
host using skin staples. Bacitracin was placed topically and a bandage put in place.
The bandages were removed at 1 week post-operatively. Mice were given carprofen in
their water for analgesia as per standard protocol.
At day 0, day 4, day 7, day 14 and 21, animals were injected with their treatments
(Figure 5). Treatment groups were; Group 1: Control, PBS treatment. Group 2: Nontargeted empty particles at 5mg per animal per treatment time. Group 3: free
mycophenolic acid at 5mg total dose injection per animal per treatment time (initially
intermittently at day 0, 4, 7, 14, 21. In a separate group [n=3] free MPA was given daily).
Group 4: Non-targeted nanoparticles loaded with mycophenolic acid at 1-10ug/mg
particles, given in total injections of 5mg particles per animal per treatment time. Group
5: CD-4 targeted (RM4-4 antibody) nanoparticles loaded with mycophenolic acid at 110ug/mg particles, given in total injections of 5mg particles per animal per treatment time
(Figure 5). Injections were done intraperitoneally. Animals were followed for rejection
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with complete rejection the primary end point. Complete rejection was considered to be
>70% scabbing over of the graft, or shedding of the graft.

In transplanted animals

treated with GK1.5, animals were given 150 ug intraperitoneal injections at five times
points (day 0, 2, 10, 14, 21).

Transplants done with CD4 knockout animals were done

identically as the other transplanted animals but no treatment was given and animals
were followed for rejection.

1.

Donor Mice
BALB/c
or

Donor Mice
B6.H-2bm12

Treatments
(Day 0, 4, 7, 14, 21
Or daily MPA)

Host Mice
C57BL/6

Control: PBS

2.

Empty Nanoparticle
(5mg/injection)

3.

Free MPA, daily or
intermittent
(5mg/injection)

4.

Non-targeted, MPAloaded nanoparticle
(5mg/injection)

5.

CD4-targeted, MPAloaded nanoparticle
(5mg/injection)

Figure 5. Study design for transplantation. BALB/c or B6.H-2bm12 mice are used to harvest
donor skin and C57BL/6 mice are used for the host. Host mice are treated on day 0, 4, 7, 14, 21
with treatment groups. After skin transplantation, mice are measured for graft survival, used to
examine ex vivo proliferation of T-cells via mixed lymphocyte reaction, dendritic cells collected
from draining lymph nodes and measured for maturation markers, numbers of regulatory T-cells
examined in peripheral blood, and graft infiltration determined by immunohistochemistry after
biopsy of the graft.

Dendritic Cell Collection
Dendritic cells were collected and grown by both Elias Kassis and Dr. Anushree
Shirali. Dendritic cells were harvested from post-treatment mice (transplant mice after
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complete rejection, or at specific time points), as well as naive mice that had not
received a skin transplant. Long bones of the mice were crushed using a mortar and
pestle and bone marrow was filtered from tissue and bone while rinsing with PBS.
RBC's were lysed using a hypotonic ammonium chloride buffer. Mixed bone marrow
cells were purified for dendritic cells using complement binding and killing with
antibodies against GK1.5, B220, GK2.43, TIB211, TIB120 and rabbit complement
incubated for one hour (Gift from the lab of Dr Ira Mellman). After purification and
counting using a hemocytometer with 64x64 grid, dendritic cells were plated in 24 well
plates at 1million cells/well and allowed to grow for 3-5 days in the presence of 1% GMCSF in RPMI media at 37º C in a 5% CO2 incubator.
Dendritic cells used for MLR or cytokine analysis. On day 3 or 5 post-incubation,
wells of dendritic cells were treated with MPA-nanoparticles at 1mg/ml, 0.1mg/ml and
0.01mg/ml. Empty nanoparticles were given at the same dosing. Free MPA was given
at doses of 5-10ug/ml, 0.5-1.0ug/ml, 0.05-0.1ug/ml and 0.005-0.01ug/ml. The range in
dose was due to different batches of nanoparticles and slight difference in loading of
MPA in each batch. The free MPA was given to roughly match the total amount of MPA
per MPA-loaded nanoparticle dose. On day 5 or 6, some dendritic cells were stimulated
with LPS (25-50ng/ml) as a maturation stimulus, and allowed to incubate for and
additional 24 hours before use.

Splenocyte and CD4 Collection
Spleens were collected from mice, homogenized, and filtered through a mesh
screen by either Elias Kassis or Dr Anushree Shirali. RBC's were destroyed using RBC
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lysis buffer (hypotonic ammonium chloride buffer) and cells were either set aside for use
or enriched for CD4 cells. CD4+ cells were enriched via negative selection using a kit
from EasySep according to the manufactures instructions (Stecell Vancouver, Canada)
that negatively selected for CD4 cells using magnetic particles and removing CD8+,
CD11b+, CD19+, CD45r+, CD49b+, Ter119+ cells. Enriched CD4 T cells were then
used for MLR.

Mixed Lymphocyte Reactions
Mixed Lymphocyte Reactions (MLR's) were undertaken using purified dendritic
cells or splenocytes from the donor BALB/C or B6.H-2bm12 mice cultured with CD4
enriched splenocytes from C57BL/6 host mice and were done by Elias Kassis and Dr
Anushree Shirali. In the initial BALB/C to C57BL/6 ex vivo experiment, mixed BALB/C
splenocytes (at 1x106 cells/well) were incubated with C57BL/6 CD4 cells that had been
isolated and pooled from mice on day 35 post-transplant (at 1 x 105 cells/well). Cells
were plated at 1:10 ratio (CD4:DCs) per well and allowed to co-incubate for 48-72hours.
In the in vitro studies, dendritic cells were incubated with nanoparticles encapsulated
with MPA (at 1mg/ml, 0.1mg/ml, 0.01mg/ml and 0.001mg/ml depending on the
experiment), empty nanoparticles (at the same doses as loaded particles), free MPA (at
8-10ug/ml, 0.8-1ug/ml, 0.08-0.1ug/ml and 0.008-0.01ug/ml), and no treatments and then
stimulated with LPS (as described in the dendritic cell section) prior to coculture with the
C57BL/6 CD4 cells.

In all experiments, the cells were co-cultured in Bruffs media

containing 10% FCS, 1% pen/strep, 50um 2ME and 2 mM L glutamine.

3

H-thymidine

was then added and the cells incubated for an additional 18-24 hours at 37º C in 5%

Kassis, Elias

Page 34

CO2 incubator. Cell proliferation was measured using a Beta plate scintillation counter
after washing and extracting 3H-thymidine from the proliferative cells using a cell
harvester from Scatron Instruments.

ELISA
ELISA analysis was done by either Elias Kassis or Dr Anushree Shirali. Mixed
lymphocyte reactions (as described) had aliquots of the supernatants collected for
analysis. DCs treated with MPA encapsulated nanoparticles, empty particles, free MPA
and no treatment were stimulated with LPS (50ng/ml) and after 24 hours the cells were
spun, and the supernatant collected for analysis. 96 well plates from Costar were used
for culture. ELISA kits from eBioscience were used. Capture antibody (IL-2, IL-6, IL-10,
IL-12, TNF, IFN) was attached overnight at 4ºC at 1:250 dilution in ELISA buffer
(eBioscience ELISA capture buffer). Plates were washed 5x and were blocked for one
hour at room temperature with ELISA assay diluent (eBioscience assay buffer provided
at 5x solution). After blocking supernatant samples were plated along with the standard
curve dilutions. The samples were incubated overnight at 4ºC and after washing were
incubated with detection antibody at 1:250 dilution in ELISA assay diluent with avidinHRP

for an additional 30 minutes and finally with superaqua blue solution (BD

bioscience)until full development.

Standard curves were created in duplicate using

standards for each antibody from E-bioscience.
HT well reader at an absorbance of 450nm.

The plates were read with a Synergy
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Flow Cytometry
Flow cytometry was done by Elias Kassis and Dr. Anushree Shirali. Cells were
collected from transplant treatment groups in vivo by harvesting the spleen or draining
lymph nodes of transplanted mice.

Cells were also collected from in-vitro cell

stimulations as described in early sections. Fluorescent antibodies against CD4, CD3,
CD11c, CD25, CD40, CD80, CD86, MHCII, B7-DC, B7-H1, Thy1.2, Annexin, 7-AAD,
Foxp3 were purchased from eBioscience and BD Pharmingen. These antibodies were
incubated with the cells at their appropriate dilution for 30 minutes at 4º and spun twice
to remove excess antibody with resuspension in PBS. Cells that were not immediately
analyzed were fixed in formalin-based fixative (BD cyotofix/cytoperm). Cells stained with
Foxp3 were permeabilized and fixed prior to incubation with antibodies as Foxp3 is an
intracellular transcription factor. The cells were analyzed using the FACS CALIBUR flow
cytometry machines in the Yale Anlyan Center flow cytometry center. Cells were gated
on lymphocytes and dendritic cells using a side scatter and forward scatter setting that
had been previously established by a member of our lab. Single stained controls were
used to set the gain and voltage in each channel and prevent overflow into neighboring
channels and the final data were uploaded and analyzed using FlowJo software
(Treestar, Ashland, OR, USA).

Histology, and Fluorescent Microscopy
Biopsies of the grafts were obtained at 15 days post-op from representative mice
by Dr Anushree Shirali. The biopsies were formalin fixed (10% formalin), and paraffin
mounted on glass slides. The tissues were H&E stained and then examined for cellular
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infiltration, signs of inflammation and other tissue characteristics using a Leica DM IRB
inverted microscope.
Dendritic cells were harvested and cultured for five days as previously described.
On day 5, 1x106 cells were collected and plated on lab-tek chamber slides (Nunc) overnight for attachment by Elias Kassis and Dr Anushree Shirali.

Coumarin 6 loaded

nanoparticles and empty nanoparticles were incubated with the plated dendritic cells.
The slides were either incubated for 2 hours or 18 hours, then washed 3x with cold PBS.
4% paraformaldehyde was used to fix the cells on ice for 15 minutes. Cells were again
washed were 3x with cold PBS, excess PBS was gently aspirated, and 2 drops of AntiFade Gold w/DapI was added.

A coverslip was placed over the cells prior to

examination under fluorescent microscopy using the green channel of the Leica DM IRB
microscope.

Nanoparticle Biodistribution
To determine the biodistribution of targeted and non-targeted nanoparticles, Noah
Capurso an MD candidate in Dr Tarek Fahmy's lab used rhodamine encapsulated
nanoparticles with either PEG alone or CD4/PEG bound to the particles as was
previously described in the nanoparticle methodology.

Particles were injected retro-

orbitally into one mouse/group/time point of harvest. Targeted particle animals were
sacrificed at 1, 5 and 24 hours and non-targeted particles were harvested at 3, 8 and 24
hours. In our laboratory, Elias Kassis and Dr Anushree Shirali compared CD4-targeted
and non-targeted coumarin-6 loaded particles with empty particles. As a control, three
naive C57BL/6 mice were given intraperitoneal injections of empty non-targeted
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nanoparticles at a total dose of 5mg. Non-targeted coumarin-6 loaded nanoparticles
were injected into a second group of animals, and targeted coumarin-6 loaded particles
injected into a third both at 5mg total dose as well. After three hours, the mice were
sacrificed. Serum was collected by removal of blood via cardiac puncture, the blood
allowed to clot, spun and serum removed from the remaining clot. The liver, spleen,
kidneys, lungs and heart were all removed, weighed and homogenized in 1 ml of
deionized water. The tissues were frozen overnight at -80ºC and after thawing were
mixed at 1:2 volume with 1% Triton X-100 in DMSO, incubated for 1hour at 37ºC to
extract dye and Frozen again overnight at -80ºC.

Homogenate was spun the following

day at max rpm for 10minutes and 200ul of the supernatant was transferred onto a black
96well ELISA plate for fluorescent reading. Standard curves were created using serial
decreasing concentrations of known coumarin-6 concentrations in the extraction
solution. Standards and samples were read using a fluorescent plate reader. The total
mass of coumarin-6/mass of tissue was calculated using the weights of the removed
organs.

Statistical Analysis
Comparison of means was performed using two tailed T-tests, and repeated
measures were compared using analysis of variance (ANOVA), with Bonferronis posttest comparison of means. Survival data between groups were compared using a LogRank analysis. All results were evaluated using Graphpad Prism statistical software
(San Diego, CA, USA). Statistical significance was considered by a p value of <0.05.
Results are reported with mean values ± standard error.
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Results
Nanoparticle drug kinetics and distribution
With the design of clinically used medications, it is important to develop drugs
that are predictable regarding their release and distribution. To understand and evaluate
the drug release from the particles, our collaborators looked at MPA-loaded
nanoparticles in solution (at physiological pH and temperature designed to simulate in
vivo conditions) and measured the release of MPA within solution over the course of a
week.

They showed the constant release profile of the nanoparticles with a linear

release rate. The release of MPA from the nanoparticles into the surrounding solution
remained steady throughout the incubation with slow and sustained release over a
seven day period (Figure 6).

Figure 6. Controlled
release graph of
cumulative MPA
release from
nanoparticles loaded
with 1 µg MPA/mg
particle in phosphate
buffered saline (PBS)
buffer at 37 °C, pH
7.4. The assay
shows that after an
initial steep rate of
release of
encapsulate MPA,
there is a constant
rate of release.

To characterize the distribution of nanoparticles within our murine model our
collaborators did a biodistribution assay of rhodamine-loaded particles. They looked at
total fluorescence of each organ (1,5 and 24 hours for CD4 targeted and 3,8 and 24
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hours for non-targeted) after retro-orbital injection of CD4-targeted and non-targeted
particles. Fluorescence was converted to ng rhodamine per gram of organ using a
standard curve and organ weights, and total rhodamine compared between groups.
They found increased levels of rhodamine in the spleen (68 ng rhodamine/g organ) at 24
hours, in the CD4 targeted group and only 4.8ng rhodamine/g organ in the non-targeted
group, but only did the study in one animal per group (Figure 7). Overall, the measured
levels of nanoparticles were much higher in each organ in the CD4-targeted group, but
only the 24 hour time point is directly comparable between groups for each organ due to
the differences in other time points.
We also looked at the biodistribution of the nanoparticles within the mouse after
intraperitoneal injection, comparing CD4 targeted-coumarin-6 loaded particle, nontargeted coumarin-6 loaded particles loaded, and empty nanoparticles. We harvested
the organs three hours post injection, but did not see any difference in fluorescence
between targeted and non-targeted treatments (data not shown).
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CD4 Targeting Flow Cytometry
Since we were using nanoparticles with CD4 targeting through the RM4-4
antibody, we wanted to determine if specific targeting was actually occurring in our
system. We examined in vitro CD4 targeting using flow cytometry. Splenocytes were
cultured in seven groups (n=1/group) with staining using CD3-PE in the FL2 channel,
CD4-PerCP-Cy5 in the FL3 channel and CD11c-APC in the FL4 channel. Treatment
groups were the following: no treatment, high (0.1mg/ml) and low (0.01mg/ml)
concentrations each of CD4-targeted particles without coumarin-6, non-targeted isotype
control (to RM4-4) coumarin-6 loaded particles, and CD4-targeted coumarin-6 loaded
particles. The results are reported as high and low concentrations of each particle group
(Figure 8,9).

The targeted coumarin-6 particles showed greater mean fluorescent

intensity in both high (MFI = 157) and low concentrations (MFI = 52) when compared to
equivalent

concentrations

of

non-targeted

coumarin-6

loaded

particles

(high

concentration MFI = 62, low concentration MFI = 27), suggesting the effectiveness for
targeting CD4 cells with nanoparticles (Figure 8). When the CD3+CD4+ cell population
was gated upon similar trends were revealed with increased mean FL1 fluorescence in
the CD4 targeted groups (high concentration MFI = 636, low concentration MFI = 176)
vs non-targeted groups (high MFI = 83, low MFI = 24) (Figure 9).
The experiment was repeated in an ex vivo model in four groups (n = 3 per
group) using a single dose (5mg of injected particle) of each particle group instead of a
high and low dose (as in the in vitro). Animals had their spleens harvested four hours
after the injection of the treatments. Mixed splenocytes were stained using CD11c-PE in
the FL2 channel and CD4-PerCP-Cy5 in the FL3 channel. The trends were maintained
in this experiment as compared with the in vitro data, with increased mean FL1
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Figure 8. Bar graphs showing
comparisons between FL1 channel
expression (coumarin-6) between
low and high concentrations
(0.1mg/ml and 0.01mg/ml) of CD4targeted and non-targeted
nanoparticles. Isotype control was
used as comparison to RM4-4 CD4
targeting antibodies. Splenocytes
were collected from naïve mice,
were cultured in vitro with
treatment groups and stained with
CD3-PE in FL2, CD4-PerCPPECy5 in FL3 and CD11c-APC in
FL4. N=1 per group
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Figure 9. A. CD3 (FL2 channel) and CD4 (FL3 channel) gating showing a distinct CD3+CD4+ double positive
population in the untreated control. B. Comparison of FL1 channel expression (coumarin-6) in the CD3+CD4+ double
positive population between hi and low concentrations (0.1mg/ml and 0.01mg/ml ) of CD4-targeted, non-targeted
nanoparticles loaded with coumarin-6 and CD4-targted particles not loaded with coumarin-6. Splenocytes were cultured
in vitro with treatment groups and stained with CD3-PE in FL2, CD4-PerCP-PECy5 in FL3 and CD11c-APC in FL4. N=1
per group

fluorescence in the CD4-targeted groups (MFI = 26.8±10) as compared to the control
(MFI = 3.5±0.75) (Figure 10). However, despite much greater mean fluorescence in the
CD4 targeted group, it was approaching statistical significance (p=0.08), but was found
to be similar to both the isotype control-coumarin-6 loaded (MFI = 10.9±1.6) and the
control, likely due to one low outlier in the CD4 targeted group (Figure 10). In these
same splenocytes stained for CD11c (in the FL2 channel) and CD4 (in the FL3 channel),
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it was found that a higher percentage of FL1 (coumarin-6) fluorescent cells are
CD4+CD11c- in the CD4-targeted group (17% in CD4-targeted vs 10% in the nontargeted group)(Figure 11, Quadrant 1). In the non-targeted group, a higher percentage
of FL1 fluorescent cells were CD11c+CD4- (9.4% in the non-targeted vs 4.6% in the

Mean Fluoresence Intensity

CD4-targeted) (Figure 11, Quadrant 3).

40
30

Coumarin 6-NP-CD+targeted
Coumarin 6-NP-isotype control
Empty NP-CD4 targeted
PBS

20
10
0

Treatment Groups

Figure 10. Ex vivo study looking at CD4 targeting in nanoparticles after collection of splenocytes from mice 4
hours post injection with treatment groups and stained with or CD11c-PE (FL2 channel), CD4-PerCP-Cy5 (FL3
channel and Thy1.2-APC (FL4 channel). FL1 measures coumarin-6 in nanoparticles. Animals were injected with
PBS, empty CD4-targeted nanoparticles (5mg particles), coumarin-6 loaded particles (5mg particles) with
isotype control or CD4 targeted coumarin-6 loaded particles (n=3 for each group). There was more fluorescence
in the CD4-targeted particles than in the control and isotype controls, but due to one outlier, the increases in
fluorescence were not statistically significant despite a large difference in mean fluorescence intensity.

BALB/C to C57BL/6 grafts
To determine the effectiveness of the MPA-loaded nanoparticles in modifying the
transplant rejection response, we first examined a full MHC mismatch BALB/C to
C57BL/6 skin transplantation (Figure 12). As expected, rejection overall was rapid in our
controls, but in this system we found significantly delayed graft rejection in non-specific
nanoparticles (NP-MPA, 1ug MPA loaded per mg NP, 5 mg NP-MPA dosed per mouse
on day 0,4,7,10,14,21; n=4) with a MST of 16 days compared with a MST of 13.5 days in
the control (p<0.01). The CD4-targeted treatments of MPA loaded nanoparticles (CD4+-
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FL3-CD4

Non Targeted C6 NP

FL1-Coumarin-6

FL2-CD11c

FL3-CD4

CD4+ Targeted C6 NP

FL1- Coumarin-6

FL2-CD11c

Figure 11. Ex vivo
experiment where mice
(n=3) were injected with
treatments and 4 hours
post injection splenocytes
were harvested and
stained for or CD11c-PE
(FL2 channel), CD4PerCP-Cy5 (FL3
channel) and Thy1.2-APC
(FL4 channel). After
negatively gating the
FL1+ population from
controls, FL1+ subgroups
were examined for CD4
and CD11c. In the
targeted nanoparticle
group, a higher
percentage of the FL1+
cells were CD4+CD11cthan in the non-targeted
group.

NP-MPA, 0.5 ug anti- CD4+ Ab [clone RM 4-4] conjugated per mg NP-MPA, 5 mg CD4+NP-MPA dosed per mouse on day 0,4,7,10,14,21; n=4) had an even greater delay with a
MST of 25 days (p<0.01 compared with the control). The survival for the CD4-targeted
nanoparticles was significantly greater than for the non-targeted particles (MST 25 days
vs 16 days, p<0.05).

The rejection in free MPA (5 mg per mouse dosed on day

0,4,7,10,14,21; n=4) and controls was statistically the same with a MST of 15 days
(p=0.06 compared with the control). Mouse skin grafts showed rapid scabbing with
eventual shedding of all grafts in all treatment groups (Figure 12).
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Figure 12. Full MHC mismatch BALB/C
to C57BL/6 skin graft rejection in mice
treated w ith free MPA (5 mg per mouse
dosed on day 0,4,7,10,14,21; n=4), or
Control
NP-MPA (1ug MPA loaded per mg NP, 5 mg
NP-MPA dosed per mouse on day
0,4,7,10,14,21; n=4) or CD4+-NP-MPA
Free M PA
(0.5 ug anti- CD4+ Ab (clone RM 4-4)
conjugated per mg NP-MPA, 5 mg CD4+NP-MPA dosed per mouse on day
NP-M PA
0,4,7,10,14,21; n=4). Control mice (n=4)
received no additional treatment after
CD4+-NP-M PA
skin grafting. Free MPA failed to improve
graft survival over the control (MST 15
vs 13.5, p=0.06). Non-targeted particles
improved graft survival (MST 16, p<0.01).
CD4-targeting resulted in robust graft
prolongation (MST 25, p<0.01 vs control)
also greater than the non-targeted
(p<0.05)

BALB/C to C57BL/6 MLR
To further characterize the phenotype that we observed with in vivo skin
transplants, we determined lymphocyte proliferation via a recall antigen ex vivo MLR.
We looked at differences between treatment groups (Free MPA 5mg/injection, CD4targeted MPA nanoparticles 5mg/dose and non-targeted MPA nanoparticles at
5mg/dose)(n=4 per group) in post-transplant C57BL/6 CD4 enriched T cells stimulated
with irradiated BALB/C splenocytes. Mice had their spleens harvested at 35 days posttransplantation. There was an equal and large decrease in proliferation as measured by
radioactive thymidine uptake in both the CD4-targeted and non-targeted animals (mean
counts per minute (CPM): CD4-targeted = 9627±36, non-targeted = 8812±696)
compared with both the control (mean CPM = 24224±2169) and the empty nanoparticle
(mean CPM = 20860±2083) (p<0.05 for both sets of comparisons) (Figure 13).
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Figure 13. Ex vivo enriched CD4+ T
cells isolated and pooled from mice
(n=4) in each treatment group (Free
MPA 5mg/injection, targeted and nontargeted 5mg/injection)on day 35
post-transplant w ere cultured in
complete Bruff’s media for 56 hours
in 96-w ell plates at 1x105 cells per
w ell along w ith irradiated BALB/c
splenocytes (1x106 cells per w ell).
3H-thymidine w as added for the last
18 hours and uptake w as measured
by a β plate scintillation counter.
Mean CPM for each group: control24224, empty NP-20860. Mean
counts per minute (CPM) w as
statistically decreased (p<0.003 **)
in both CD4-targeted and nontargeted treatments

We also looked at In vitro MLR with C57BL/6 CD4 enriched splenocytes
cocultured with BALB/C irradiated splenocytes cultured for 72 hours in each treatment
group (Free MPA at 10ug/ml, 1ug/ml, 0.1mg/ml; N-MPA and empty-NP at 0.1mg/ml and
0.01mg/ml and control)(n=3 per group) and found a significant decrease in proliferation
in free MPA groups in a dose dependent manner (Figure 14) (MPA 10mg/ml mean CPM
= 42.5±6.3, MPA 1mg/ml mean CPM =76.6±36.6, MPA 0.1mg/ml mean CPM =329±54.7)
compared to the control group (mean CPM = 8708±840) (p<0.05 for each MPA dose vs
the control). Nanoparticles loaded with MPA also showed a dose dependent decrease in
proliferation (NP-MPA 0.1mg/ml mean CPM = 80.7±24.4, NP-MPA 0.01mg/ml mean
CPM=1880±58.9) compared with the control (p<0.05 for each group).

Empty

nanoparticles showed a much greater proliferation response (NP 0.1mg/ml mean CPM=
5582±850, NP 0.01mg/ml mean CPM=7104±278) than the equivalent concentrations of
MPA-loaded particle (NP vs NP-MPA at 0.1mg/ml, p=0.003; NP vs NP-MPA at
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0.001mg/ml, p<0.0001) and a statistically similar proliferation with the controls (Figure
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Figure 14. In vitro enriched splenic CD4+ T
cells from naive B6 mice were co-cultured with
irradiated BALB/c splenocytes in a one-way
MLR without added treatment or treatment
with free MPA, graded doses of empty NP
(NP), or graded doses of NP encapsulated
MPA (NP-MPA). NP were encapsulated with 6
μg of MPA per mg of NP. Compared to no
treatment, empty NP had no significant effect
on T cell proliferation at either dose of NP (NP
0.1 mg/ml, P=0.06; NP 0.01 mg/ml, P=0.14),
whereas compared to no treatment, NP
encapsulated MPA inhibited proliferation at
both doses (NP-MPA 0.1 mg/ml, P=0.005; NPMPA 0.01 mg/ml, P=0.001). For comparison
of NP vs. NP-MPA, * denotes P=0.0001 and
** denotes P=0.003. Graph only shows one
dose of free MPA as the other doses were
similar and equally low

B6.H-2bm12 to C57BL/6 grafts
In order to further test and characterize the efficacy of CD4 targeting delivery of
MPA, we transferred to a single MHCII mismatch CD4 dependent system for both in vivo
and in vitro studies. We repeated skin grafts in B6.H-2bm12 to C57BL/6 mice (Figure
15). Both targeted CD4-NP-MPA (MST = 39days, p=0.0004) and non-targeted NP-MPA
loaded (MST = 33days, p=0.002) nanoparticles show significantly delayed transplant
rejection as compared with no treatment (MST = 19.5 days). Targeted (p=0.01) and non
targeted MPA loaded (p=0.05) particles also show delayed rejection when compared to
intermittent free MPA dosing (MST = 22 days). There was no statistical difference in
graft survival between the targeted and non-targeted MPA groups. Daily free dosing
(MST = 26 days) showed no significant difference in survival compared with the
intermittent free MPA and both CD4-NP-MPA and NP-MPA. Daily free MPA delayed
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rejection as compared with the control as well (p= 0.01). Targeted empty (MST = 18)
and non-targeted empty nanoparticles (MST = 20) had similar graft rejection as
compared with the no treatment group (Figure 15). In this less immunogenic model (as
compared to BALB/C to C57BL/6), overall graft rejection was less rapid, but complete
rejection was still found in all treatment groups.

B6.H-2bm12 --> C57BL/6 T ransplant Survival
100

No T reatment (n=10)
F ree MPA (n=6)

Percent survival

80

Non-targ eted MPA-NP (n=11)
T argeted MPA-NP (n=11 )

60

T argeted emp ty NP (n=4)
F ree MPA- daily dosing (n=3)
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Figure 15. Skin graft survival in B6.H-2bm12 graft
to C57BL/6 host mice, single MHCII mismatch
model. Mice were treated with free MPA (5 mg per
mouse dosed on day 0,4,7,10,14,21; n=6), or NPMPA (1ug MPA loaded per mg NP, 5 mg NP-MPA
dosed per mouse on day 0,4,7,10,14,21; n=11) or
CD4+-NP-MPA (0.5 ug anti- CD4+ Ab (clone RM
4-4) conjugated per mg NP-MPA, 5 mg CD4+-NPMPA dosed per mouse on day 0,4,7,10,14,21;
n=11. Control mice received no additional
treatment (n = 10). Mean survival times (MST)
was significantly increased in both CD4-targeted
(MST 39, p=0.0001) and non-targeted (MST 33,
p=0.002)MPA-particles compared with NoRx
mice (MST 19.5). Both targeted and non-targeted
MPA-particles increased MST over intermittent
free MPA (MST 22, p<0.05) but not over daily free
MPA(MST 26). Targeted and non-targeted MPAparticles had similar MST. All controls had similar
MST(18-20 days).

Survival of CD4 ko and GK1.5 Rx Skin grafts
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Figure 16. Skin graft survival
data in B6.H-2bm12 graft to
C57BL/6 host mice treated
with PBS (control) B6.H2bm12 graft to C57BL/6 host
mice ttreated with GK1.5
depleting antibody, or B6.H2bm12 graft to C57BL/6 -CD4
k/o host mice. CD4 k/o
accepted grafts indefinitely.
GK1.5 treated mice had
statistically increased MST of
32 days over control mice
MST of 19.5days (P<0.006).
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CD4 k/o and GK1.5 Transplantation
Rejection in B6.H-2bm12 to C57BL/6 graft was shown to be a CD4, MHCII
dependent process. We looked at skin transplants in a CD4 knockout mouse on a
C57BL/6 background receiving a B6.H-2bm12 skin graft. CD4 knockout mice failed to
reject their skin grafts, with eventual complete graft acceptance (Figure 16).
Furthermore, in animals treated with GK1.5, an antibody to CD4 that inhibits function, we
found delayed graft rejection (MST =32 days, p<0.006) as compared with control groups
(MST 19.5 days). However all animals treated with GK1.5 eventually had complete graft
rejection (Figure 16).

Rejection Histology
In order to observe the cellular response within the graft and the differences in
response between treatment groups, skin graft biopsies were collected for histology on

A.

B.

D.

E.

C.

Figure 17. Representative skin graft
histology from day 15 post transplantation
with H+E staining. Images are all at 10x
magnification. A. No Treatment control
mice showing a robust inflammatory
response. B. Free intermittent MPA
treatment also showing signs of rejection
with infiltration and inflammatory cells.
C.
Non-targeted MPA-nanoparticles showing
decreased inflammation qualitatively
compared with control. D. CD4-targeted
MPA nanoparticles showing decreased
inflammation compared to controls.
E.
CD4-targeted empty nanoparticles showing
inflammation and signs of graft rejection.
Arrows indicate areas of inflammation, stars
indicate skin sloughing off.
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day 15 from representative mice within each treatment group. Histology of the skin graft
showed increased inflammation and cellular infiltration with increased signs of acute
rejection. The targeted and non-targeted MPA-loaded nanoparticle treatment groups
exhibited less lymphocytic infiltration and decreased overall signs of acute rejection
(Figure 17). The observations were qualitative and no formal scoring system was used
for comparison.

B6.H-2bm12 to C57BL/6 MLR
Lymphocyte proliferation and the effect of MPA and MPA-loaded particles was
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also examined via MLR and showed a decrease in proliferation after culture with MPA-

loaded nanoparticles.

Figure 18. C57BL/6 splenocytes were CD4+ T
cell enriched and cocultured in a one-way
MLR with B6.H-2bm12 BMDCs that had been
previously cultured for 24h with LPS, free
MPA, empty NP or NP-MPA at increasing
concentrations listed in the figure in 96-well
plates at 1x10^5 cells per well along with the
irradiated DC's (1x10^6 cells per well). 3Hthymidine was added for the last 24 hours and
uptake was measured by a β plate scintillation
counter. Mean CPM was decreased in all
concentrations of nanoparticles loaded with
MPA (NP-MPA) (p<0.03 * for each
comparison) compared with control. NP-MPA
at all concentrations was decreased compared
with free MPA at all concentrations as well
(p<0.05 * for each comparison).

Our in vitro MLR used C57BL/6 splenocytes cocultured with

B6.H-2bm12 bone marrow derived dendritic cells that had been been previously cultured
with increasing free MPA concentrations, increasing empty particle and increasing MPAloaded particle concentrations (Figure 18).

NP-MPA at 0.1mg/ml (mean CPM
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=2808±261, p<0.01), at 0.01mg/ml (mean CPM = 3484±457, p<0.02) and 0.01mg/ml
(mean CPM =3071±1026, p<0.03) were all significantly decreased from the control
(mean CPM = 8918±794). NP-MPA treated groups were also significantly decreased
(p<0.05) from the free MPA groups (MPA 0.1mg/ml CPM = 7136±458, MPA 0.01mg/ml
CPM = 6294±565, MPA 0.001mg/ml CPM = 7930±1098) (Figure 18). Due to a problem
with the extraction, the ex vivo results were not interpretable for comparison.

Particle Uptake in Dendritic Cells
As we hyopthesized that dendritic cells were involved in the phenotype that we

A.

B.

C.

D.

E.

F.

Figure 19. Incubation of cultured DC's collected from bone marrow with nanoparticles for 2 hours
with images obtained at 20x magnification using a fluorescent microscope A. Shows coumarin-6
fluorescence in the green-fluorescent channel in loaded-nanoparticles incubated with DC's.
B.
DAPI counter-staining of the nucleus in the coumarin-6 loaded incubation. C. Overlay of green
and blue channels coumarin-6 and DAPI staining shows nanoparticles in attached to cell surface,
within the cytosol and possibly at different stages of phagocytosis. D. Green-channel
fluorescence in DC's cultured with empty particle control. E. DAPI nuclear counter stain. F.
Overlay of green and blue channel in empty particles.

Kassis, Elias

Page 51

observed with similar graft rejection between targeted and non-targeted nanoparticles,
we wanted to see if DCs would take up nanoparticles while in culture.

DCs were

incubated on slides overnight for attachment. Uptake of nanoparticles was examined by
comparing DCs cultured with coumarin-6 loaded particles with empty particles at 2 hours
and 18 hours of incubation. At both 2 hours and 18 hours the coumarin-6 loaded
particle-treated groups showed increased DC uptake of nanoparticles with increased
fluorescent signal compared to the controls (Figure 19). Furthermore, the fluorescent
signal appeared to be both diffusely increased in the cytoplasm as well as focally
increased in nanoparticles attached to the cell membrane in what may appear to be
varying stages of phagocytosis (Figure 19).

Cytokine Activation
To characterize the inflammatory response and the modulation that we expected
to find with treatment using MPA-loaded nanoparticles, we also looked at cytokine
profiles. The supernatant from MLR with culture of pre-treated DCs from B6.H-2bm12
mice with CD4 enriched C57BL/6 cells was analyzed for IL-2 production via ELISA. IL-2
production appeared to be decreased in a dose dependent fashion with increasing
doses of MPA-loaded nanoparticles (N-MPA0.1mg/ml mean IL-2 concentration = 382±17
pg/ml, p<0.005; N-MPA 0.01mg/ml mean IL-2 concentration = 523±62 pg/ml, p<0.02; NMPA0.001mg/ml mean IL-2 concentration = 636±6 pg/ml, p<0.01) compared to the
control (Figure 20). Increasing doses of free MPA also showed decreased production in
a dose dependent manner (MPA10ug/ml mean IL-2 concentration = 262±11 pg/ml,
p<0.004; MPA1ug/ml mean IL-2 concentration = 661±10 pg/ml, p<0.01; MPA0.1ug/ml
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mean IL-2 concentration = 695±24 pg/ml, p<0.02; MPA0.01ug/ml mean IL-2
concentration = 800±46 pg/ml, p<0.03) compared with the control (No Rx mean IL-2
concentration = 1251±57 pg/ml). (Figure 20). IFN-gamma levels (although we expected
them to be low) were unchanged between treatment groups, nor did we find an increase
in IL-10 production in the MPA-loaded particles (data not shown). Overall numbers were
low in these experiments and were therefore difficult to interpret.
IL-2 production from MLR supernatant

Figure 20. IL-2 production from
MLR coculture of B6.H-2bm12
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DC's at 1x106 cells/well with
C57BL/6 CD4 enriched
splenocytes at 1x105 cells per
well after treatment of DC's with
increasing doses of free MPA,
nanoparticles encapsulating MPA
and empty nanoparticles. Free
MPA at all concentration showed
a decrease in IL-2 production
compared with control (p<0.03*
for each comparison) N-MPA at
all concentrations decreased IL-2
(p<0.02 ** for all comparisons).

In addition to the MLR cytokine production, we also looked at the profiles of
activated dendritic cells in the presence or absence of NP treatments. DCs that were
pre-treated with free MPA, empty particles, MPA-loaded particles and control groups
were then stimulated with LPS and production of IL-6 and IL-12 was measured (Figure
21). IL-6 cytokine production was significantly decreased in N-MPA at all concentrations
(N-MPA0.1mg/ml

mean

IL-6

concentration

=

63738±4055

pg/ml,

p<0.05;

N-

MPA0.01mg/ml mean IL-6 concentration = 53339±3664 pg/ml, p<0.05) compared with
the NoRx +LPS control (mean IL-6 concentration = 132671±2295 pg/ml). Free MPA was
also found to decrease IL-6 production (MPA9ug/ml mean IL-6 concentration =
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40815±1661 pg/ml, p<0.01; MPA0.9ug/ml mean IL-6 concentration = 43483±1855 pg/ml,
p<0.01) compared with the control. IL-12 was also reduced in one experiment by doses
of N-MPA (N-MPA0.1mg/ml mean IL-12 concentration = 22306±141pg/ml, p<0.05; NMPA0.01mg/ml mean IL12 concentration = 44919±871 pg/ml, p<0.05).

Free MPA was

also able to decrease IL-12 at 9mg/ml (mean IL-12 concentration= 36054±270 pg/ml,
p<0.05) and 0.9mg/ml (mean IL-12 concentration = 54403±900 pg/ml, p<0.05) (Figure
21). We did not find any up-regulation of IL-10 in these tests either, and downregulation

Il-12 in DC's incubated with Rx Groups
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of TNF was also not seen (data not shown).

Figure 21. IL-12 and IL-6 production from DC's. DC's were collected from
C57BL/6 bone marrow grown for 5 days, incubated with treatment groups for 24
hours, and subsequently stimulated with LPS for an additional 24 hours. Both
free MPA and Nanoparticles encapsulating MPA showed a decreased production
of both IL-12 and IL-6 compared with control (p<0.05 *).

DC Maturation Markers
As we thought that MPA-loaded nanoparticles may be affecting dendritic cells, we
also looked for any changes in costimulatory and maturation surface markers on DCs
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after treatment. Draining lymph nodes from transplanted mice were harvested on day 15
and cells were stained for DC maturation markers with CD40-FITC, CD80-FITC, MHCIIPE and CD86-APC.

Cells were run on flow cytometry to determine differences in

surface expression and gated on CD11c+ populations. CD40, CD80 and MHCII surface
expression was unchanged in animals treated with free MPA, non-targeted-nanoparticles
loaded with MPA and CD4-targeted nanoparticles (Figure 22). CD86 expression was
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Figure 22. Draining
lymph nodes were
collected from mice on
day 15 post-transplant.
Lymphocytes were
stained ex vivo with DC
maturation markers
CD40-FITC, MHCII-PE,
CD80-FITC and CD86APC. There were no
difference in CD40 (A),
MHCII (B) or CD80 (C)
between groups. D.
CD86 showed a
significantly decreased
CD86 surface expression
via mean fluorescence
intensity (MFI) with both
targeted and nontargeted treatments (n=3,
p<0.05) compared with
controls (stars = p<0.05).

significantly decreased in both targeted (MFI = 38±2, p<0.005) and non-targeted (MFI =
39±3, p<0.02) MPA-loaded particle treatment groups (n=3/group) (Figure 22). In vitro
DCs were also stained with CD80, CD86, CD40 and MHCII after 3 days of proliferation
and subsequent 24 hours of treatment with free MPA, N-MPA and empty particles, and
no differences were found in surface expression in the CD11c gated population (data not
shown).
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Treg proliferation
Regulatory T cells have been shown to be involved in decreased immune
responses to transplantation (64), so we also looked for increases in Tregs after
treatment with MPA-loaded nanoparticles.

At day 21 post-transplant we collected

splenocytes from our treatment mice (Free 5mg MPA, targeted and non-targeted N-MPA
at 5mg particle) and stained the cells ex vivo with CD4-APC (FL4 channel), CD25-FITC
(FL1 channel) and Foxp3-PE (FL2 channel). We gated on side and forward scatter for

Lymphocyte Gate
Subgate: CD4+

Lymphocyte Gate Subgate:
CD4+CD25+

Foxp3

*

125

MFI - FL2

100

*

**

75
50
25
0

Untreated

Free MPA

Figure 23.E x vivo
splenocytes were
collected at day 21 posttransplantation and were
stained with CD25-FITC,
CD4-APC andfoxp3-PE
Lymphocytes were gated
with FSC and SSC, and
foxp3 (FL2) mean
intensity (MFI) was
compared between
treatment groups
(n=3/group). Free MPA
and NP-MPA showed
significant increases in
fluorescence (p<0.05 *)
and CD4-NP-MPA showed
highly significant increase
in fluorescence
(p<0.003**)

NP-MPA CD4-NP-MPA

lymphocytes and looked at the CD4+CD25+ population of cells and compared mean
fluorescence intensity of Foxp3 (FL2). We found an increased MFI in free MPA (MFI =
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111±11, p<0.05) in non-targeted particles (MFI = 94±5, p<0.05) and in CD4-targeted
particles (MFI = 115±4, p<0.003) (Figure 23).

Apoptosis Flow Cytometry
To determine if there were increases in dendritic cell death through apoptosis, we
collected DCs after incubation with our treatment groups for flow cytometry. We stained
DCs with 7-AAD (FL3 channel), Annexin (FL1 channel) and CD11c-APC (FL-4). We
gated on a DC population using forward and side scatter and subgated on the FL4
channel to capture CD11c+ cells, and determined relative percentage of cells
undergoing apoptosis in each group (Figure 24). Apoptotic cells were determined as 7-
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Figure 24. DC's incubated with treatment groups were collected and stained with annexin (FL1),
7AAD (FL3) and CD11c-APC(FL4). Populations were gated on DC population via SSC vs FSC and
gated further on CD11c+ populations. Apoptotic cells were considered 7AAD negative, Annexin
positive. A. Diagram showing FL1 vs FL3 channels. B. graph of percentage of cells from the third
quadrant of every treatment group showing increased apoptosis in N-MPA groups. (n= 1 for each
group)

AAD negative, Annexin positive. There was more apoptosis in both MPA loaded (10%
7AAD-Annexin+) and empty nanoparticles (9% 7AAD-Annexin+) at high concentrations
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(0.1mg/ml) without sufficient data to run statistics (n=1 per group) (Figure 24).

B7-DC and B7-H1 Flow Cytometry
B7-DC and B7-H1 have been shown to be important negative co-stimulatory
molecules that may be involved with dendritic cell decrease in T cell antigen response.
We were interested to determine if these molecules were involved with the phenotype
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that we observed in our system. In DCs that were pretreated with MPA-loaded particles,

Figure 25. Mean fluorescence intensity of DC's stained with B7DC-FITC and B7H1-PE. A,B. Results from first
experiment (n=1 for each group) with increased expression in the 0.2 mg/ml MPA-NP group. C,D. Experiment was
repeated with two different mice showing a consistent increased expression of both B7-DC and B7-H1 on DC's treated
with MPA-loaded nanoparticles (at 0.1 mg/ml) and gated on CD11c+ population. In the second experiment, B7-DC and
B7-H1 fluorescence were both statistically increased compared with the control group (p<0.05 *). Data was not
combined between the first and second experiments due to difference in gating and staining.

empty particles, free MPA and no treatment, we found consistently elevated mean
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fluorescence looking at B7-H1 and B7-DC surface expression in groups treated with
0.1mg/ml MPA-loaded particles. Our initial experiment (n=1) showed this trend in both
B7-DC (NP-MPA0.1mg/ml fluorescence = 158, control fluorescence = 68) and B7-H1
(MPA0.1mg/ml fluorescence = 1424, control fluorescence = 842) (Figure 25). Repetition
of the experiment with an additional two animals confirmed the results with significant
increase in surface expression of both B7-DC (MFI = 134±21, p<0.05) and B7-H1 (MFI =
146±16, p<0.05) compared with the control (Figure 25).

Kassis, Elias

Page 59

Discussion
Summary
MPA-loaded particles showed a slow and continuous release profile in vitro and
biodistribution demonstrated a possible increased nanoparticle retention in the spleen.
We showed effective targeting of nanoparticles to CD4 T cells using both ex vivo and in
vitro analysis by flow cytometry. In the fully allogeneic MHCII mismatch BALB/C to
C57BL/6 mice we found improved graft survival in the non-targeted MPA group and even
greater graft survival in the CD4-targeted group, as well as decreased proliferation with
both targeted and non-targeted nanoparticles using in vitro and ex vivo mixed
lymphocyte reactions. In the less immunogenic B6.H-2bm12 to C57BL/6 transplants, a
single MHC-II mismatch model, we found equal and increased graft survival in both the
CD4 targeted and non-targeted animals.

In both the highly immunogenic and less

immunogenic models, graft survival times were increased over free drug using the
nanoparticle encapsulation and the total dose of drug given to attain this increased
survival was roughly one thousand fold lower than the free drug concentration. We also
showed that the B6.H-2bm12 to C57BL/6 model was CD4 dependent by administration
of the depleting antibody GK1.5 and by transplanting skin from a B6.H-2bm12 mouse
onto CD4 knockout mouse bred onto a C57BL/6 background. It was postulated that the
similar rejection times in targeted and non-targeted groups was due to dendritic cell (DC)
involvement and we found active uptake of nanoparticles in DCs, a decrease in
inflammatory cytokine production and a decrease in treated DCs ability to stimulate T
cells via mixed lymphocyte reactions. Furthermore we found a possible mechanism of
nanoparticle-MPA action on the DC interaction with T cells through the upregulation of
the inhibiting co-stimulatory molecules B7-DC and B7-H1 on DCs treated with MPA-
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nanoparticles. These ligands bind the PD-1 receptor on activated T cells and have been
implicated in a decreased immune response. We also found possible upregulation of
CD4+CD25+ Foxp3 expressing T cells which may serve to increase graft acceptance.
These results indicate the feasibility of nanoparticles loaded with immunosuppressive
drugs to be used clinically and illustrate the involvement of dendritic cells in the process
of nanoparticle induced graft acceptance.

B6.H-2bm12 to C57BL/6 Survival
The results of our graft survival show that CD4-targeted and non-targeted MPA
loaded particles significantly delay graft rejection by two to three weeks over the control
groups.

The results also showed that targeted particles do not significantly delay graft

rejection over non-targeted particles despite a mean survival time increase of an
additional six days in the B6.H-2bm12 to C57BL/6 transplants. It is possible that the
study was under-powered to show subtle differences between these two groups, but it is
also possible that there is no actual difference between targeted and non-targeted
nanoparticle treatments with both groups working very well to delay transplant rejection.
The intermittent free drug was significantly less effective at decreasing graft
rejection as compared with the MPA-loaded particles. Mycophenolate mofetil in its oral
form exhibits peak blood concentrations of MPA at 1-2 hours after conversion in the liver
to its active form. It also exhibits a mean half-life between 9-17 hours, with great intersubject variability. Because of this, it is generally dosed twice a day in humans (65).
Therefore, our intermittent free drug treatments were large doses quickly cleared by the
mouse. Due to this clearance, there were multiple days where MPA blood levels were
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likely very low until the next treatment with MPA.

We did not examine the

pharmacokinetics of MPA in our mice, but we thought that the intermittent dosing was
not an optimal comparison to our nanoparticles despite the thousand fold lower dose in
the nanoparticles. To address this we included in our study a daily intermittent dosing in
one of our later transplant groups. Due to the low number of animals in this treatment
group we did not achieve a statistically significant difference in mean survival time
compared to either the intermittent free MPA or with either of the MPA encapsulated
nanoparticles, even though the MST was four days longer than the intermittent free drug
and 13 days shorter than the MST for targeted nanoparticle treated groups.
Nevertheless, it is interesting that daily free drug in doses that are more than a thousand
fold greater STILL do not show improved graft survival than the nanoparticle delivered
MPA. This is consistent with literature showing that nanoparticle encapsulated drugs
can be conveyed with better efficacy due to the delivery characteristics of the
nanoparticles (59). Furthermore, our results agree with literature showing that single
dose injections of PLGA nanoparticles encapsulated with drug can have equal in vivo
efficacy as daily injected doses of the drug (42).

Some studies have even found

improved efficacy of single dose PLGA nanoparticle injections as compared with multiple
free drug injections (66). This delay in graft rejection is also clearly not secondary to
effects of the empty nanoparticles alone as empty particles that are targeted and nontargeted show the same mean survival time as the non-treated group. In addition, the
histology confirms the robust inflammatory response seen in the control groups and the
decrease in cellular infiltration and inflammation in the nanoparticle-MPA treatment
groups with delayed rejection.
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BALB/C to C57BL/6
It is also interesting that in our small data set using BALB/C to C57BL/6 skin
transplants, we found significantly greater graft survival in the targeted MPA-nanoparticle
group when compared to the non-targeted MPA-nanoparticle group. This difference
might represent the small numbers of animals in each group and be due to insufficient
power, but it may also represent a different phenotype as compared with the less
immunogenic B6.H-2bm12 to C57BL/6 transplants (as the difference was statistically
significant with a p<0.05). In skin-grafted mice, the migration of MHC class II donorderived dendritic cells (DCs) to the recipient’s lymph nodes triggers a potent direct CD4
T cell alloresponse. Skin grafts can be rejected directly or indirectly by both CD4 and
CD8 cells activated against both MHC and minor antigens in a major mismatch model
such as a BALB/C to C57BL/6 skin transplant. Interestingly however, one group that
looked at B6.H-2bm12 to C57BL/6 skin grafts found only the direct allopresentation
response in their model (62). This is of interest within our study due to the phenotypic
difference in rejection between the highly immunogenic BALB/C to C57BL/6 and the less
immunogenic B6.H-2bm12 to C57BL/6 graft. If the highly immunogenic model relies
upon both direct and indirect allorecognition, and the indirect response is absent from
the less immunogenic B6.H-2bm12 to C57BL/6 model, than perhaps this explains the
observations in the targeted and non-targeted groups in both models.

This has

interesting possible implications as it may suggest that targeted nanoparticles in the
BALB/C to C57BL/6 affect the indirect pathway to greater degree (increasing MST in
targeted treatments) and with this presentation pathway absent in the B6.H-2bm12
transplants, perhaps this contributes to the similarity between targeted and non-targeted
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groups. This interaction has not been examined in the literature, but it may be worth
further study. To test this you could utilize models that isolate either the direct or indirect
pathways, and compare targeted and non-targeted nanoparticle treatments within each
model. These models may be created using transgenic mice (such as CD11c-DTR
transgenic mice that can be conditionally depleted of CD11c+ DCs with administration of
diphtheria) that impair DC function/antigen presentation (back-crossed or bred on
BALB/C, C57BL/6 and B6.H-2bm12 mice) as both donor and recipient mice.

The

indirect pathway may be isolated using our current models with depletion of donor DCs
within the skin graft before prior to transplantation. These may be interesting avenues of
study because if the indirect pathway is affected more by targeted nanoparticles, this
could have implications for the elusive treatment of chronic rejection, as the indirect
pathway has been implicated in chronic rejection pathogenesis(17).

MLR interpretation
Interestingly, despite the difference in targeted and non-targeted treatments in
vivo of graft survival times in the BALB/C to C57BL/6 mice, the ex vivo MLR on these
animals showed a reduction in proliferation that was equal between the targeted and
non-targeted groups.

Although the flow cytometry data likely indicated successful

targeting with CD4-targeted particles, it is unclear how well targeting actually induces a
down-regulation of alloimmune cells, as the decrease in proliferation was equal in the ex
vivo targeted and non-targeted groups.

This finding may also simply represent a

difference between a transplant response and a MLR in the behavioral response to
MPA-loaded particles and be an artifact of the assay itself. Unfortunately, the ex vivo
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data from our B6.H-2bm12 transplants were not interpretable after technical problems
during the radioisotope extraction, so we are not able to compare in vivo to ex vivo
results in the B6.H-2bm12 transplants. The in vitro data from both transplant models are
consistent showing a decreased proliferation with MPA-loaded particles. Unfortunately,
we were not able to test the specific interaction of nanoparticles with CD4 T cells in our
MLR as CD4 T cells remain in suspension and cannot be separated for subsequent
culture with dendritic cells and splenocytes. In the future we may attempt to flow-sort the
sample to isolate T cells from suspension (as long as T cells are not non-specifically
activated by flow sorting).

In our BALB/C model the co-incubation of irradiated

splenocytes, CD4 T cells and treatment groups likely showed particle interactions with
both CD4 T cells and the APCs in the splenocytes. Initially we thought that irradiation of
the splenocytes would decrease phagocytosis and lead to a response that was reliant
upon the CD4 T cell uptake of nanoparticles, but there does not appear to be any
literature that clearly shows that APC irradiation decreases phagocytosis, and therefore
the response we found is likely due to nanoparticle interaction with both cell types. In
our B6.H-2bm12 in vitro MLR's we found a response that was dependent strictly on
pretreatment of DCs. We cultured the nanoparticles with DCs before coculture with CD4
T cells which points to the involvement of DCs in our in vivo skin graft rejection
phenotype.

Our MLR's therefore were able to show nanoparticle affects on the

proliferative response through DCs but were not able to show an affect through CD4 T
cells alone. Overall however, the results of these MLR's are consistent with our graft
survival data, and consistent with the observed in vitro changes in cytokine expression
with an overall decreased inflammatory and proliferative response.
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CD4 dependence and targeting
It was important to determine the CD4 dependent nature of the B6.H-2bm12 to
C57BL/6 model, to make sure that the effect that we saw from treatment was secondary
to CD4 T cell activity. Using GK1.5 depleting antibody against CD4, we saw a modest
increase in graft survival although a change that was less than expected (still statistically
significantly greater than the control). It is possible that the doses of antibody used were
insufficient to decrease a proliferative response, and that a larger dose of GK1.5 would
have increased mean graft survival longer. Furthermore with only three animals in this
group, we may have had too few animals to properly see the larger difference. Using a
CD4 knockout mouse as the recipient allowed for acceptance of the graft showing the
CD4 dependent rejection in our model. Since CD4 T cells regulate both the cytotoxic
and humoral allospecific response of CD8 and B-cells, the CD4 knockouts likely have
reduced overall immunity leading to graft acceptance. The results of both our GK1.5
and CD4 knockout mice are in agreement with a study looking at pancreas xenografts
from rat to mouse that was shown to be CD4 dependent similarly to our model but in a
different organ system and model. GK1.5 treatments delayed graft rejection, while CD4
knockout mice showed acceptance of the graft in a model that suggested dependence
on CD4 cells for rejection (67).
The discovery that non-targeted nanoparticles loaded with MPA displayed equal
skin graft prolongation as the targeted particles in our B6.H-2bm12 to C57BL/6 mice was
initially a surprise. It is unclear if this lack of difference was due to poor targeting of the
nanoparticles. Targeting was suggested with the flow cytometry with increased FL1
channel signal in the targeted coumarin-6 particles as compared with the non-targeted
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particles. The ex vivo data were not shown to be significant however due to the small
number of samples (with one outlier) and this needs to be repeated to truly prove
targeting. Despite this lack of significance, in the targeted nanoparticle group the FL1
coumarin-6 positive cell population had an increased percentage of cells in the
CD4+CD11c- subpopulation.

In the non-targeted nanoparticle treatment, the FL1

coumarin-6 positive cell population had an increased population in the CD11c+CD4subpopulation.
CD4+CD11c-

The increased number of coumarin-6 fluorescent cells in the
population

with

targeted

nanoparticles

indicated

that

specific

binding/uptake in CD4 cells was likely greater than the non-specific/binding/uptake in
DCs expressing CD11c. In addition our collaborators have consistently found targeting
with these same particles in their previous studies using anti-CD3 (48)(32) and in their
unpublished data showing success with anti-CD4 targeting as well. One question that
remains unclear though (as it does with most flow cytometry comparisons) is how any
observed difference in fluorescence would actually translate into a meaningful clinical or
functional difference. The data from our collaborators comparing retro-orbital injections
of PEGylated rhodamine loaded PLGA particles compared with CD4 targeted particles
showed increased retention in the spleen after injection in the targeted particles, but this
data is difficult to interpret as it was only done in one mouse/group, and the CD4
targeted particles appeared to be retained in all organs to a greater degree than the nontargeted particles. These data would need to be repeated to determine any significance.
Furthermore a difference in biodistribution alone would not prove targeting, but the large
CD4 population in the spleen would explain any increased retention compared with nontargeting.

The lack of difference in biodistribution that we found at three hours post

intraperitoneal injection may be due to retention in the peritoneum (as opposed to direct

Kassis, Elias

Page 67

introduction into the vasculature with retro-orbital injections) and a longer time may be
needed post injection to be able to find systemic differences in nanoparticle retention.
Overall, our data suggests successful targeting, but needs to be repeated to determine
the consistency of these findings.

Dendritic Cell Involvement
We postulated that our targeted and non-targeted nanoparticles may be
exhibiting two different mechanisms abrogating graft rejection and increasing mean
survival times of skin grafts in our B6.H-2bm12 model. The CD4-targeted particles likely
increase transplant acceptance through their activity directly on CD4 T cells via cytosolic
delivery of MPA while the non-targeted particles induce acceptance through some other
pathway that was initially unclear to us (with CD4-targeted particles likely acting through
this pathway to some degree as well). The flow cytometry data from our ex vivo animals
showed increased FL1 signaling and hence increased binding/uptake of the nontargeted particles in the CD11c+CD4- subgroup that makes up the dendritic cell
population. This indicated to us that dendritic cells possibly were actively taking up the
non-targeted nanoparticles and suggested to us that the non-targeted particles may be
yielding their effects through activity on the dendritic cells.

As DCs are important

scavengers and sentinels of the periphery with enormous influence on the fate of T cell
populations (68), we speculated that uptake of nanoparticles into dendritic cells may be
involved in our observed phenotype.
It was suggested in one study that dendritic cells exert a powerful influence in
skin graft transplant models due to the higher than normal numbers of dendritic cells that
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are resident within skin compared with other tissues (62). Dendritic cells in general have
a great influence on transplant rejection, which has consistently been shown throughout
the transplant literature. The direct and indirect antigen presentation pathways have
been shown to be vital in presentation of foreign antigen and development of an
allogenic immune response (15) . Dendritic cells exert their influence on the rejection
process in multiple different ways, and are the important front-line cells in the detection
and allospecific response to foreign antigens (68). It has been shown that the peak size
of the allospecific T cell population is an important factor in the speed and robustness of
the rejection (69). It has also been shown that an important factor in the peak size of
this T cell population is the number of antigen presenting cells that are activated (70),
with larger numbers of activated DCs leading to a larger T cell response.

Overall,

dendritic cells increase the transplant response through their direct and indirect
activation of T cells, presentation of costimulatory molecules and production of excitatory
cytokines (15).
Dendritic cells have also been shown to be involved in the down-regulation of the
transplant rejection immune response.

This down-regulation could be through their

absence, decreasing the number of activated antigen presenting cells and subsequently
decreasing the alloreactive T cell population, but DCs have also been shown to directly
down-regulate the immune response as well. This action is through their production of
ligands for negative costimulation, decreased activation of T cells with changes in
cytokine profiles and induction of tolerant anergic responses via immature dendritic cells
and up-regulation of CD4+CD25+ regulatory T cells (71).
MPA uptake via nanoparticle delivery may lead to inhibition of dendritic cells
which in turn would lead to decreased activation of graft specific T cells. Our microscopy
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of dendritic cells cultured with nanoparticles showed robust phagocytosis of the particles
by dendritic cells.

Furthermore, we found a decreased mixed lymphocyte reaction

response with B6.H-2bm12 dendritic cells treated with MPA-nanoparticles cocultured
with C57BL/6 CD4 cells. This in vitro response indicated that dendritic cells were likely
less able to activate T cell proliferation after the DCs had been exposed to MPAnanoparticles.

Qualitatively it was also noticed that the DCs treated with the

nanoparticles appeared to be less healthy in appearance and formed fewer clusters in
culture which may have been an indication of decreased function, and decreased ability
to activate a T cell response. In addition, we found decreases in inflammatory cytokine
expression in DCs cultured with MPA-particles. With regard to the in vivo rejection
response, these cumulative data suggested that DCs may have been responsible.

MPA and Dendritic Cells
Recently it was shown that dendritic cells are inhibited by exposure to MPA. In
one study the investigators found that immature human DCs exposed to MPA were
induced to a mature phenotype yet showed a decreased allogeneic T cell activation
through both the direct and indirect pathways (72). Another study suggested that MPA
was able to decrease the functional maturation of dendritic cells, finding both decrease
maturation markers as well as functional decreases in inflammatory cytokine production
(73). As dendritic cell trafficking to lymph nodes for antigen presentation is an important
aspect of the development of the acquired immune response, one group has been
looking at the affects of MPA on dendritic cell trafficking in blood samples taken from
healthy human volunteers.

They found that MPA decreased the expression of
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chemokine receptor 7 (CCR7) and increased the expression of CCR1 (upon maturation
DCs suppress CCR1 and switch to increased expression of CCR7) which correlated with
a decrease in DC homing to lymphatic tissues (as CCR7+ cells are drawn by
chemotactic gradient towards lymphatic tissues) thus inhibiting a crucial step in the
initiation of an alloimmune response. They also found a generally immature phenotype
of DCs treated with MPA, impaired activation via TLR3 ligation and decreased T cell
activation via MLR (74).
Our results examining cytokine production indicated that our DCs after treatment
with MPA and MPA-loaded particles could be involved in the down-regulation of the
immune response. We found decreases in IL-6 and IL-12 in our free MPA, and nanoMPA treatments after stimulation with LPS consistent with the literature showing a
decrease in inflammatory cytokines produced by DCs after treatment with MPA.
Similarly to our study, Lagaraine et al. and Mehling et al. also found decreases in IL-12
production by their DCs treated with MPA. As IL-6 production has been shown to
require p38MAPkinase (75), and p38MAPkinase has been shown to be inhibited by MPA
(76), our decrease in IL-6 that we found is understandable. Consistent with this as well
were our results showing decreased IL-2 production in our MLR supernatants in the
groups with DCs pretreated with MPA and MPA-nanoparticles, which was also consistent
with the decrease in proliferation via MLR that we found in these treated groups.
Similarly to Lagaraine et al., after culturing DCs with MPA loaded nanoparticles
we did not find a shift to an immature phenotype as we found no differences in surface
MHC, CD80 or CD86 expression via flow cytometry either ex vivo or in vitro.

Our

collaborators in Dr Fahmy's laboratory, however, while using a similar nanoparticle
(modified from our PLGA particles) examined coculture with DCs from an early time
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point starting at day 1 of DC culture and in the MPA-loaded particle group they were able
to find a shift in the maturity phenotype to an immature form with decreased surface
expression of CD40, CD80 and CD86 (unpublished data).

As their particles were

slightly different in structure from ours and they started incubation at Day1 instead of
Day3 or Day5 like we did in our experiment, the change that they found may be due to
either of these factors and we are planning on recapitulating the data using an earlier
time point for culture. Our ex vivo data are difficult to compare with the in vitro data
obtained by other investigators. Our results however are similar to Lagaraine et al. who
found decreased activation with MPA treated DCs (similarly to us) but in the context of a
mature phenotype (72). The difference in maturity phenotype may be related to the time
point of DC exposure to MPA. Lagaraine et al. similarly to our study did not begin
exposure of DCs until 5+ days after beginning the culture, and they did not find any
change in maturity phenotype. However, both Mehling et al. and Cicinnati et al. found an
overall decrease in DC maturity but both of their studies cultured their DCs with MMF or
MPA from day one of DC culture (73) (74). Consistent with the literature, the difference
in our results are likely explained by the timing of the treatment, but we would need to
repeat the in vitro study to determine if this is in fact true.
Overall, the literature indicates that MPA pushes the immune system towards
decreased immunity through interactions not just with T and B cells but through
interactions with antigen presenting cells causing decreased antigen presentation,
decreased direct and indirect alloimmunity, decreased APC function and increased
overall graft acceptance. It remains unclear however the mechanism by which MPA
exerts these effects on DCs. As MPA inhibits IMPDH, this has been examined as a
possible pathway within the DCs. One group found that MPA decreased p38MAPKinase
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However, exogenous

guanosine failed to reverse the effects of MPA in DCs leading the researchers to
speculate that MPA exerted its effects on DCs independent of IMPDH (76).

The

mechanism however remains elusive.

Regulatory T cells
Regulatory T cells (Tregs) are a group of T cells that have an immunomodulatory
role in the development of antigen-specific immune responses. There was initially a
great deal of controversy as to to existence and role of Tregs after early research in the
1970's led to their suggestion (77). In the early 1990's however, a group found that the
observed transplantation tolerance in their study could only be due to Treg involvement
(78). This paper furthered the idea of “infectious” tolerance that had been suggested by
Gershon et al. in 1971, and Qin et al. found that the transfer of CD4 T cells from tolerant
mice were able to induce tolerance in naive lymphocytes and that these newly tolerant
lymphocytes were able to subsequently induce tolerance in another naive group; hence
their “infectious” nature (78). This work has since caused an explosion in research
looking at Tregs with much focus on Tregs in transplantation. The most recognized and
best studied group of Tregs are “natural” Tregs produced in the thymus that are
CD4+CD25+ and express Foxp3 which is a transcription factor that is essential to Treg
growth and differentiation (79). The development of CD4+CD25+ Tregs has been shown
to be dependent upon the cytokines IL-10 (80) and TGF-beta (81). Tregs appear to
modulate transplant rejection with their ability to induce antigen specific tolerance, with
upregulation of CD4+CD25+ T cells that are specific to alloantigen decreasing the graft
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specific immune response (64). Multiple pathways have been explored to determine the
nature of this interaction and DCs appear to both affect and be affected by Tregs (71).
DCs have been shown to be capable of expanding Treg CD4+CD25+ positive
populations (82) and Tregs have been shown capable of decreasing maturation and
functionality of DCs (83).
There has also been work looking into the interaction of MPA and DCs with
Tregs. One study using porcine dendritic cells found low expression of B7 costimulatory
molecules,

low levels of IL-12 production and generally weak proliferative mixed

lymphocyte reactions when DCs were cocultured with peripheral blood mononuclear
cells (PBMC's). They also found that after multiple exposures to MPA treated DCs,
PBMC's inhibited the alloproliferative response likely indicating an induction of Treg cells
capable of modulating the alloimmune response (84). Another study has shown that
DCs treated with MPA increased the antigen specific Treg population possibly increasing
the level of tolerance to antigen specific responses (85).
As the literature also suggests that MPA and DCs can contribute to the formation
of Tregs, we examined this interaction in our model as well. We looked for expression of
cytokines that lead to Treg production such as IL-10 (86), but were unable to detect any
differences in production between groups. We plan to measure TGF-beta, which is a
classic stimulator of Treg formation (86) as well. Despite no differences in cytokine
production in our treatment groups in vitro that would push differentiation to Treg
formation, our flow cytometry data with staining for CD4, CD25 and Foxp3 showed a
likely proliferation of Tregs in our MPA treatment groups. We need to repeat this in more
mice for confirmation, but the experiment indicates a statistically significant increase in
fluorescence for Tregs in the CD4-targeted animals, free MPA and non-targeted MPA-
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nanoparticles when comparing mean fluorescence intensities. It remains unclear why
we may have an increase in Treg development in the absence of increased cytokines as
the literature looking at DCs and MPA pushing a Treg phenotype finds a parallel increase
in IL-10 and TGF-beta (85), but perhaps this difference is due to our testing conditions.
Our increase in Tregs was found ex vivo roughly three weeks post-transplant, while our
in vitro testing for cytokine up-regulation was via MLR, DCs treated with MPA and
nanoparticles for 24 hours and a short DC/CD4 co-culture without secondary stimulation
after co-culture.

Lagaraine et al. in 2008 found an up-regulation of Treg inducing

cytokines using a 5-day coculture MLR with secondary re-stimulation with antiCD3/CD28 as well as an extended length 4-week coculture, and in both shorter and
longer experiments the cultures were treated continuously with MPA (85). Our lack of IL10 cytokine expression therefore is not surprising considering the much shorter duration
of interaction between DCs and CD4's and the decrease in nano-MPA treatment times in
our in vitro experiments compared with the literature.

Role of PD-1 and PD-1 Ligands
The role of co-stimulation in T cell activation has been well established in the
development of the alloimmune response (87). The CD28:B7 costimulation is the most
well understood of these co-stimulatory interactions and has been shown to be involved
in the initiation of T cell responses (88)(89).

To counter-balance these “excitatory”

signals, the body has the ability to negatively co-stimulate as well. CTLA-4 which is
induced after T cell activation also binds to B7 on APCs and has been shown to be an
important inhibitor of T cell function (90). The role of CTLA-4 is exhibited dramatically in
animals that are CTLA-4 knockouts as these animals die rapidly from massive
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lymphoproliferation (91).
Our discovery of up-regulation of B7-DC and B7-H1 in our mice treated with MPA
loaded nanoparticles was a very intriguing finding. The programmed death-1 (PD-1)
receptor is a recently uncovered molecule that exhibits negative regulation of T cells. It
is a member of the CD28 family and was cloned from T cells undergoing apoptosis (92).
Unlike other members of the CD28 family, PD-1 has been found on CD4, CD8, B-cells
as well as myeloid cells, but is especially prevalent on activated T cells (93). Two
ligands for PD-1 have been discovered, PD-L1 (B7-H1) and PD-L2 (B7-DC) both in the
B7 family but distinct from B7-1 and B7-2 that are involved in T cell costimulation. PDL1(B7-H1) has been found on activated APCs such as dendritic cells, monocytes and B
cells (94).

Induction of expression on peripheral APCs has been found secondary to

exposure to inflammatory cytokines, while PD-1 expression is found on predominately
on activated T cells (95). Thus, the interaction between this receptor-ligand appears to
be critical in regulation of effector and memory T cells with local modulation of specific T
cell responses as sites of inflammation.
The role of PD-1 in tolerance has also been clearly shown with its expression on
the placenta during pregnancy and its location in a position that might help facilitate
protection against the mothers' immune system (96). In addition, both PD-L1(B7-H1)
knockout mice and mice treated with antibody blocking PD-L1 rejected semi-allogeneic
pregnancies but accepted syngeneic pregnancies (97), further illustrating the importance
of the PD-1 pathway in immunogenic tolerance.
important
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immunity especially
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encephalomyelitis (98)(99)(100)(101).
The PD-1 pathways has been strongly implicated in modulation of the T cell
response.

In one study examining PD-1 involvement in heart graft rejection, PD-1

appeared to down-regulate alloreactive T cells.

The same study also showed that

blockade of PD-L1 (B7-H1) increased the speed of allograft rejection, further solidifying
the role in T cell modulation (102).

In another study by this same group using an

adoptive transfer of T cells antigenically specific to the mutated MHC class II molecule IAbm12 (our B6.H-2bm12 mice), they found that PD-L1(B7-H1) blockade enhanced T cell
proliferation, inhibited allospecific T cell apoptosis and skewed the response to a Th1
phenotype (103). PD-1 has also been implicated with Tregs, as one study found a
decrease in Treg numbers in PD-L1(B7-H1) knockout mice (104). Another study found
that blockade of the PD-1:PD-L1(B7-H1) pathway abrogated Treg immunoregulation
suggesting that the pathway is necessary for Treg function and upregulation (105).
Recently, a group in Boston demonstrated that PD-L1(B7-H1) has a pivotal role in the
regulation of induced Treg development as well as the maintenance of the Treg
response. They found that PD-L1 (B7-H1) knockouts are only able to minimally induce
Tregs, and that PD-L1(B7-H1) coated beads are able to induce Tregs. In addition they
found that PD-L1(B7-H1) increases the expression of Foxp3 and sustains the
immunosuppressive function of the cells, clearly implicating PD-1 and its ligand B7-H1
as centrally important in Treg maintenance and function (106). Numerous other studies
have also implicated PD-1 as an important part in the upregulation of Tregs.

This

connection is intriguing within our study as we have found both an increase in Tregs, as
well as an upregulation of the PD-1 ligands B7-DC and B7-H1 in our nano-MPA treated
groups. The literature strongly supports a connection between these separate findings
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and our graft rejection phenotype may be due to both an upregulation of the PD-1
pathway through enhanced expression of the PD-1 ligands B7-DC and B7-H1 with a
possible subsequent Treg proliferation.

Despite this information however, it is not

completely clear how PD-1 and the PD-1 ligands regulate T cell function, and is likely not
through a single pathway, but through a combination of apoptosis, induction of anergy
and immunoregulation.
Interestingly, evidence is building that the PD-1 receptor is not the only receptor
involved in the effects of the PD-L1, and binding effects may be more wide spread. In
vivo blockade of PD-1 results in different effects then blockade of PD-L1. Sandner et al.
showed that blockade of PD-L1 significantly decreased the amount of apoptosis, but
blockade of PD-1 failed to decrease the apoptosis response (103).

Another study

suggested that PD-L1 in tumor cells was able to induce apoptosis of T cells specific to
the tumor in a non-PD-1 mediated manner (107). Uncovering these other receptors may
be valuable in further understanding how the PD-1 ligands B7-H1 and B7-DC are fully
involved with modulating the immune response.

PD-1 and MPA
Recently, a group published a report uncovering a connection between the
programmed death ligand system and treatment with MPA (108). They observed that the
PD-1:PD-L interaction in T cells inhibits cytokine production, proliferation and results in
cell cycle arrest. They also observed that the affect of MPA on dendritic cells was similar
and hypothesized that this novel receptor-ligand interaction might be involved in the
behavior seen in DCs treated with MPA. In agreement with previous work, they found
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that MPA decreased the allostimulatory behavior of DCs in a dose dependent manner.
They also found a down-regulation of costimulatory/maturation molecules including
MHCII, CD80 and CD86 also consistent with previous reports, and they found a
decrease in Th1 profile cytokines (108). This decrease in maturation markers with the
early treatment of DCs with MPA is consistent with the results found by other
investigators that treated DCs with MPA early in their growth (73) (74). Interestingly,
Geng et al. also made the novel finding that MPA treated DCs upregulated PD-L2 (B7DC) also in a dose dependent manner, without any difference seen in PD-L1 (B7-H1)
(108).

While this finding does not prove causation, it certainly suggests possible

involvement of the PD-1 inhibitory pathway in the observed effects of MPA on DCs and
their role in modulation of T cell activation. In related studies, it has been reported that
MPA affects MAPkinase pathways independent of IMPDH pathways in DCs (76). A
different group found that PD-L2:PD-1 interaction upregulated MAPkinase in T cell's
(109). Therefore, the interactions between the MAPkinase pathways, PD-1 and MPA,
may be an interesting avenue of exploration to determine the connection between MPA
and PD-1.
Our findings showing up-regulation of B7-DC and B7-H1 in our MPA-nanoparticle
treated dendritic cells are therefore consistent with the results of Geng et al. and the
delay in transplant rejection that we found in our non-targeted group may be due in part
to the up-regulation of these negative co-stimulatory molecules secondary to the effects
of the MPA nanoparticles. We also found a small increase (not significant) in apoptosis
and cell death with flow cytometry staining for annexin and 7-AAD, although these
results would need to be repeated to determine if they are consistent, significant and not
an artifact of the particles themselves (as empty particles also showed an increase in
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this population). However, if this increase apoptosis is real, it may be secondary to the
MPA treatment as it has been suggested in previous studies that found increased
apoptosis in DCs treated with MPA (110)(72). It remains unclear the mechanism of
action that may cause induction of apoptosis as MPA may affect both the IMPDH
pathway and other unknown pathways (76). However, increased apoptosis may also be
through the B7-DC and B7-H1 pathways, as these have also been shown to be involved
in the induction of apoptosis in other immune cell types (107). Overall, the expression of
PD-L1 (B7-H1) on a dendritic cells appears to be a functionally relevant and important
pathway in the development of tolerance to transplantation (71), and its interaction with
immunosuppressive medications and use to induce transplant acceptance will be a
valuable direction for further research .

Role of Nanoparticles in Transplant
Much of the research investigating nanoparticle modulation of transplant rejection
by other investigators has limited translatability and comparability to our study, as the
models that other studies have employed are dramatically different from skin
transplantation. The corneal transplant models used by multiple researchers looking at
encapsulated tacrolimus, sirolimus and cyclosporine are generally avascular, and are
likely very different in physiology from other transplantations. It is difficult therefore to
extrapolate from these studies to other forms of transplantation. The susceptibility of T
cell mediated transplant rejection has been shown to be very different depending on the
type of graft tissue and the location of the graft placement (111).

Indeed, corneal

transplants and skin transplants represent the extreme ends of allogenicity and
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immunogenicity. It has been shown countless times in the C57BL/6 – BALB/C model
that mice will rapidly reject their skin transplants over the course of 1-2 weeks, and that
this rejection is only moderately modifiable with general resistance to transplant
modification treatments. Skin allografts are therefore considered the most immunogenic
of all transplanted tissues (16).
In contrast, the corneal transplant in these same mice is very well tolerated
without any treatment, and roughly 50% of grafts are spontaneously accepted, with the
remaining grafts slowly rejected over 8-10 weeks. Furthermore, this slow rejection is
easily modifiable using immunosuppressive agents (16).

This sensitivity to

immunosuppressive agents may be due to the fact that the cornea itself is poorly
immunogenic and the eye is a site of immune privilege (112). It has been shown in a
study comparing skin and corneal transplants that the skin transplants reject through
both direct and indirect pathways by both CD4+ and CD8+ cells activated against both
MHC and minor antigens. Corneal transplants however, only reject via CD4+ T cells that
are indirectly activated against minor histocompatability antigens (16). If Schenk et al.
are correct that our B6.H-2bm12 mice reject through only a direct pathway (62), then
the skin transplants used in our study would respond in a dramatically different fashion
from a corneal transplant.
The comparison of our research to the work of Alemdar et al. using dopaminergic
CNS transplantations (55)(56), exhibits similar problems for relation to our study as the
corneal transplant research. The central nervous system is also an immune privileged
site similarly to the eye (113) and transplant rejection and tolerance is likely mediated by
factors that are different from the highly immunogenic allogenic skin graft. The CNS
produces a number of anti-inflammatory molecules which decrease the overall
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MHC expression on resident immune cells has been

shown to be relatively low, decreasing T cell activation and proliferation. The blood brain
barrier maintains this protection so despite its vascularization it is relatively protected
from the rest of the body (113). Overall it is difficult to determine the applicability of the
findings of Alemdar et al. compared with our system because of both the type of
transplanted tissue as well as their use of liposomal particles (not PLGA like in our
study).
The comparisons to these other models illustrates a potential limitation of our
work in translation to clinical allografts. Similarly to the difference between rejection of
corneal and CNS transplant and skin transplants, the biology of skin graft rejection may
also be different from solid organ vascularized grafts used clinically such as the heart,
kidney, lung and liver. Skin appears to be the most immunogenic transplanted graft, with
lung and small bowel also causing a robust immune response.

In decreasing

immunogenicity are pancreatic islets, vascularized pancreas, heart, kidney and liver
transplants (114) (111). Liver allografts are sufficiently non-immunogenic to be accepted
without treatment in many animal models (115). Our model with skin allografts which
initiate the most robust immune response may therefore not represent the same
response that might be seen in other tissues.

In skin transplants which are not

vascularized, the histologic findings of acute and chronic rejection involving immune
invasion and deposition within the vascular walls will not be found. Non-vascularized
grafts are also more susceptible to ischemic damage (116) leading to non-specific
inflammation and necrosis which may allow the graft to become more affected by the
targeted immune response.

This increased sensitivity however has been largely

dismissed as evidence has mounted that vascularized skin grafts also reject with similar
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The mechanism behind the increased

immunogenicity of skin allografts remains unclear but other possibilities have been
proposed including the presence of tissue specific antigens in the skin. The skin also
serves as an immunologic barrier and thus has large numbers of dendritic cells with
subsequent ability to robustly activate alloreactive T cells. Recent work showed that
highly immunogenic skin grafts tend to require a lower number of effector T cells for
rejection when compared to other solid organs like heart transplants (69)(62).
The work that is most directly comparable to our study was done by McAlister et
al. who used liposomal tacrolimus to treat both skin allografts and heart allografts. They
compared oral free vs oral liposomal drug and found improved skin graft survival with the
liposomal formulation and unchanged survival of the heart allograft (58). Ultimately, this
study is also difficult to compare with our own because this study delivered drug orally
and used liposomal particles instead of PLGA particles, but overall it is in agreement with
our results finding that nanoparticle encapsulated drug can be superior to free drug in
highly immunogenic skin transplantation.
Due to these differences in graft behavior, future studies could move to one of
two models that we have had experience with in our lab. The pancreatic islet transplant
is less immunogenic and technically can be done with relative ease.

Our lab has

recently started using this model in aging studies (unpublished data), and this less
immunogenic model might be able to tease out differences between CD4-targeting and
non-targeted nanoparticles that we were unable to see in our skin graft model. An even
greater improvement to our model would include using vascularized heart allografts.
These transplants require far more technical expertise, surgical skill and time than the
skin transplants we are currently employing, but this model would represent a human
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solid organ transplantation much better than either a skin or pancreatic islet
transplantation. We have had some experience in our lab with these transplants as well
(117), and perhaps this would be a worthy future direction to consider.
Another area that would further strengthen the argument for use of nanoparticles
in transplantation modulation would be to study targeting of nanoparticles encapsulated
with other drugs such as tacrolimus, sirolimus and cyclosporine. Mychophenolic acid is
an effective drug that has largely replaced azathioprine, but it is generally only used in
combination with other medications as maintenance therapy, is rarely used alone and
rarely for induction of immunosuppression (21). MPA is generally taken orally as the
pro-drug mycophenolate mofetil and is actually fairly well tolerated compared with many
other immunosuppressive medications. Therefore, MPA may not ultimately be the best
drug for this technology to be used with. Multiple groups have had success already with
rapamycin (49) cyclosporine (52)(50) and tacrolimus (53) encapsulation in PLGA
particles for use in corneal transplants.

Our collaborators have indicated that

encapsulation of these drugs would be possible in their laboratory as well and this may
present another interesting future approach to our work.
As clinically used immunosuppressives are given orally, it would also be
interesting for us to develop an oral form of targeted nanoparticles. Oral formulations
may be preferential in terms of compliance, ease of use and ability to treat away from a
hospital or clinic.

Using oral nanoparticles would be superior to using intravenous

treatments, and this would be a valuable direction to take our research in the future.
Oral preparations of liposomal drugs have been used to many years (doxirubicin,
vincristine, amphotericin), and McAlister et al. even looked at oral liposomal tacrolimus
(58), but there has been little work looking at oral PLGA encapsulation of
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One group has used PLGA particles encapsulated with

cyclosporine as an oral treatment (40). Cyclosporine, due to its high molecular weight,
rigid structure and the P-glycoprotein intestinal cellular efflux mechanisms (P-gp efflux)
present in the GI system causes overall low bio-availability with oral intake. Nanoparticle
encapsulation bypasses the P-gp efflux, decreases gastrointestinal tract degradation
and gut wall metabolism and improves pharmacokinetic profiles and bio-availability.
Nanoparticles can also allow protection from first pass liver metabolism as happens with
traditional oral drugs (40). This group found that nephrotoxicity was decreased in the
nanoparticle group and that the nanoparticle formulation exhibited consistent and
controlled slow release with better bio-availability and intestinal uptake (40). These data
indicate that PLGA particle oral formulations may have a viable future in transplantation
and that it may be interesting to use oral formulations of MPA loaded particles in our
transplant model.

Conclusion
Despite the little previous research that has been done looking at nanomedicine
in transplant, it appears that this field has great potential and that nanoparticles will likely
be an important avenue for the improvement of drug delivery. The medical management
and treatment of patients post-transplantation is currently limited by the efficacy and
dose-toxicity of the currently available immunosuppressive medications.

With the

considerable expense of developing new medications, the possibility of encapsulation of
currently used drugs in nanoparticles with improved pharmacokinetics, local drug
delivery and improved side effects make this avenue an attractive option. A bright future
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of medicine lies in targeted therapies that deliver drug locally to specific tissues or cell
types and spare the rest of the body from the deleterious effects, and targeted
nanoparticles will likely be part of this future. Our research sets the stage for these
therapies as our work is the first antibody or ligand targeted nanoparticle research in a
transplant model.

Our work suggested that targeted and non-targeted MPA-loaded

particles are both capable of increasing graft survival at thousand-fold lower doses in
vivo, and that MPA-loaded particles decrease lymphocyte proliferation with MLR, finding
possible differences in efficacy of targeting dependent upon the immunogenicity of the
model. We also found that targeting particles likely show specificity to CD4 T cells.
Furthermore, we examined the mechanistic effects of our particles within our model with
results suggesting dendritic cell involvement with uptake of MPA-loaded particles and
subsequent decrease in the alloimmune response with up-regulation of Tregs,
upregulation of the inhibitory costimulatory molecules B7-DC and B7-H1, and decreased
inflammatory cytokines with MPA-loaded nanoparticles.

Overall our research is a

starting point to develop further clinically relevant nanoparticle-drug combinations, and
further uncover and investigate the basic pathways and interactions underlying
nanoparticle modulation of the transplant immune response.
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